Therapeutic Dendrimers

Cabazitaxel-conjugated dendrimers address solubility and delivery challenges by enhancing therapeutic efficacy and reducing toxicity, achieving prolonged drug release and improved bioavailability.

JP7588065B2Active Publication Date: 2024-11-21STARPHARMA PTY LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2021501311
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-07-19
Filing Date
2019-07-19
Publication Date
2024-11-21
Estimated Expiration
2039-07-19

Smart Images

  • Figure 0007588065000084
    Figure 0007588065000084
  • Figure 0007588065000085
    Figure 0007588065000085
  • Figure 0007588065000086
    Figure 0007588065000086
Patent Text Reader

Abstract

Provided herein is a dendrimer comprising a core unit, five generations of building units that are lysine residues or analogs thereof, a first terminal group comprising a cabazitaxel residue covalently linked to a diglycolyl linker group, and a second terminal group comprising a PEG group. Also provided herein are pharmaceutical compositions comprising the dendrimer, as well as methods and uses of the dendrimer in treating disorders such as cancer. Also provided are methods for preparing dendrimers and intermediates. [Selected Figure] Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present disclosure generally relates to drug-dendrimer conjugates comprising dendrimers comprising a core unit and building units, the outermost generation of the building units comprising one or more pharma- ceutically active agents attached via a cleavable linker group. The present disclosure also relates to pharmaceutical compositions and methods of treatment comprising the drug-dendrimer conjugates, as well as methods and synthetic intermediates for producing the drug-dendrimer conjugates. [Background technology]

[0002] There are several difficulties associated with the formulation and delivery of pharma- ceutically active agents, including poor water solubility, toxicity, low bioavailability, instability under biological conditions, lack of targeting to the site of action, and rapid in vivo degradation.

[0003] To overcome some of these difficulties, pharma- ceutically active agents can be formulated with solubilizing agents that may themselves cause side effects such as hypersensitivity and may require premedication to reduce these side effects. Alternative approaches include encapsulation of pharma-ceutically active agents in liposomes, micelles or polymer matrices, or binding of pharma-ceutically active agents to liposomes, micelles and polymer matrices.

[0004] Although these approaches have the potential to ameliorate some of the challenges associated with formulation and delivery of pharma- ceutical active agents, many still have drawbacks.

[0005] Tumor drugs are particularly difficult to formulate and can have side effects that can limit the dosage and regimen that can be used for treatment.This can lead to reduced efficacy of treatment.For example, taxane drugs such as cabazitaxel have low water solubility, but also have a relatively narrow therapeutic window, so that increasing the concentration of the drug, for example by using solubilizing excipients, can cause related toxicity issues.

[0006] The use of liposomes, micelles and polymer matrices as carriers to encapsulate or bind pharmaceuticals while allowing the solubilization of pharmaceutically active agents and, in some cases, improved bioavailability and reduced toxicity, presents difficulties with regard to the release of pharmaceutically active agents.In some cases, the carriers degrade rapidly, releasing the pharmaceutically active agents before they reach the target organ.In other cases, the release of pharmaceutically active agents from the carriers is slowed to such an extent that it is not possible to achieve a therapeutic dose of the drug in the body or in the target organ.In addition, such compositions may present stability and manufacturing challenges.

[0007] Thus, there is a need for alternative formulations and means of delivering drugs that are stable, practical to manufacture, and have a generally homogenous composition, while reducing side effects, improving dosing regimens, and improving the therapeutic window, which may lead to better patient compliance and efficacy of the drug. Summary of the Invention

[0008] The subject matter of the present disclosure is based, in part, on the surprising discovery that conjugating cabazitaxel to a dendrimer provides improved efficacy and / or pharmacokinetic properties of the drug.

[0009] Thus, in a first aspect, i) a core unit (C); ii) a building unit, wherein each building unit (BU) is a lysine residue or an analogue thereof; Including, The core unit is covalently linked to two building units via amide bonds, each amide bond being formed between a nitrogen atom present in the core unit and a carbon atom of an acyl group present in a building unit; It is a 5th generation building unit dendrimer; The building units of different generations are covalently linked to each other via amide bonds formed between a nitrogen atom present in one building unit and a carbon atom of an acyl group present in another building unit; iii) a plurality of first terminal groups (T1), each of which comprises a cabazitaxel residue covalently attached to a diglycolyl linker group; iv) a plurality of second end groups (T2), each of which comprises a PEG group; A dendrimer further comprising at least one-third of the nitrogen atoms present in the outer building units are each covalently bonded to a first end group; At least one-third of the nitrogen atoms in the outer building units are each covalently bonded to a second end group. A dendrimer, or a pharma- ceutically acceptable salt thereof, is provided.

[0010] In some embodiments, the core is: JPEG0007588065000001.jpg2741. In some embodiments, the building units are each: JPEG0007588065000002.jpg2447; where the acyl group of each building unit provides a covalent attachment point for bonding to the core or a previous generation building unit; and each nitrogen atom provides a covalent attachment point for covalently bonding to a subsequent generation building unit, the first terminal group or the second terminal group.

[0011] In some embodiments, the building units are each: JPEG0007588065000003.jpg2752.

[0012] In some embodiments, the dendrimer has five complete generations of building units.

[0013] In some embodiments, each first end group (T1) is: JPEG0007588065000004.jpg4959.

[0014] In some embodiments, the second terminal group comprises a PEG group having an average molecular weight in the range of 1000 to 2500 daltons.

[0015] In some embodiments, the second terminal groups each comprise a PEG group covalently bonded to a PEG linking group via an ether bond formed between a carbon atom present in the PEG group and an oxygen atom present in the PEG linking group (L1), and each second terminal group is covalently bonded to a building unit via an amide bond formed between a nitrogen atom present in the building unit and a carbon atom of an acyl group present in the PEG linking group.

[0016] In some embodiments, each of the second end groups is JPEG0007588065000005.jpg2260 The PEG group is a methoxy-terminated PEG having an average molecular weight in the range of about 1750 to 2500 daltons.

[0017] In some embodiments, the dendrimer comprises a surface unit comprising exterior building units attached to a first end group and a second end group, the surface unit having the following structure: JPEG0007588065000006.jpg3964, where the PEG group is a methoxy-terminated PEG having an average molecular weight in the range of about 1750-2500 daltons.

[0018] In some embodiments, the dendrimer has 28 to 32 surface units, preferably 30 to 32 surface units.

[0019] In some embodiments, at least 40% of the nitrogen atoms present in the outer building units are each covalently bonded to a first end group; and at least 40% of the nitrogen atoms present in the outer building units are each covalently bonded to a second end group.

[0020] In some embodiments, five generations of building units are complete generations, with the outer generation of building units providing 64 nitrogen atoms for covalent attachment to a first end group or a second end, with 26-32 first end groups covalently attached to one of said nitrogen atoms, and 28-32 second end groups each covalently attached to one of said nitrogen atoms.

[0021] In some embodiments, the cabazitaxel residues make up the w / w % of the dendrimer in the range of 23% w / w to 28% w / w.

[0022] In some embodiments, the dendrimer is: JPEG0007588065000007.jpg6374 (wherein T1' represents the first terminal group JPEG0007588065000008.jpg4255 or T1' represents H, and T1' is less than 5 H; T2' represents the second end group JPEG0007588065000009.jpg2054, where the PEG group is a methoxy-terminated PEG having an average molecular weight in the range of about 1750 to 2500 daltons, or T2' represents H and less than five of T2' are H.

[0023] In some embodiments, the in vitro half-life of cabazitaxel release from the dendrimers in PBS at pH 7.4 and 37° C. ranges from 20 to 100 hours.

[0024] In some embodiments, the in vitro half-life of cabazitaxel release from the dendrimers in PBS at pH 7.4 and 37° C. ranges from 30 to 60 hours.

[0025] In a second aspect, there is provided a composition comprising a plurality of dendrimers or pharma- ceutically acceptable salts thereof, comprising: dendrimer is as defined herein; the average number of first end groups per dendrimer in the composition is in the range of 24 to 32; the average number of second end groups per dendrimer in the composition is in the range of 24 to 32; A composition is provided.

[0026] In some embodiments, the cabazitaxel residues constitute a w / w % of the dendrimer in the composition in the range of 23% w / w to 28% w / w.

[0027] In some embodiments, the composition is a pharmaceutical composition, and the composition comprises a pharma- ceutically acceptable excipient.

[0028] In a third aspect, i) a dendrimer as defined herein, or a pharma- ceutically acceptable salt thereof; and ii) a pharma- ceutically acceptable excipient. A pharmaceutical composition comprising:

[0029] In some embodiments, the composition is a solid composition comprising a dendrimer, a sugar and an acid as defined herein, wherein the composition is for reconstitution with a diluent.

[0030] In some embodiments, the sugar is trehalose and the acid is citric acid.

[0031] In some embodiments, after reconstitution with diluent, the reconstituted composition has a pH in the range of 3.5 to 5.5.

[0032] In some embodiments, a composition comprises a dendrimer as defined herein and includes a sugar and an acid, and a diluent.

[0033] In some embodiments, the composition is free or substantially free of polyethoxylated castor oil and polyethoxylated sorbitan monooleate.

[0034] In some embodiments, the composition is formulated for administration as an infusion over a period of up to 30 minutes, or the composition is formulated for administration as a bolus over a period of up to 5 minutes.

[0035] In a fourth aspect, there is provided a dendrimer or a pharmaceutical composition as defined herein for use in therapy.

[0036] In some embodiments the dendrimer or pharmaceutical composition is for use in the treatment of cancer.

[0037] Also provided is a method of treating cancer comprising administering a therapeutically effective amount of a dendrimer or pharmaceutical composition defined herein to a subject in need thereof.

[0038] There is also provided the use of a dendrimer or composition as defined herein in the manufacture of a medicament for treating cancer.

[0039] In some embodiments, the cancer is selected from the group consisting of pancreatic cancer, prostate cancer, breast cancer and ovarian cancer.

[0040] In some embodiments, the cancer is metastatic castration-resistant prostate cancer (mCRPC).

[0041] In some embodiments, the therapeutically effective amount of the dendrimer is between 10 and 100 mg / m 2 This is the range of body surface area.

[0042] In some embodiments, the therapeutically effective amount of the dendrimer is between 20 and 50 mg / m 2 This is the range of body surface area.

[0043] In some embodiments, the therapeutically effective amount of the dendrimer is 50-100 mg / m 2 This is the range of body surface area.

[0044] In some embodiments, the composition is administered as an infusion over a period of up to 30 minutes, or the composition is administered as a bolus over a period of up to 5 minutes.

[0045] In some embodiments, the dendrimer is administered in combination with an additional therapeutic agent.

[0046] In some embodiments, the dendrimer is administered in combination with an additional anti-cancer drug.

[0047] In some embodiments, the dendrimer is JPEG0007588065000010.jpg6274 (wherein T1' represents the first terminal group JPEG0007588065000011.jpg4558 or T1' represents H, and less than 5 of T1' are H; T2' represents the second end group JPEG0007588065000012.jpg1854, where the PEG group is a methoxy-terminated PEG having an average molecular weight in the range of about 1750 to 2500 daltons, or T2' represents H and less than five of T2' are H.

[0048] In some embodiments, administration of the dendrimer provides therapeutically effective plasma concentrations of cabazitaxel for a longer period of time compared to administration of an equivalent dose of free cabazitaxel.

[0049] In some embodiments, administration of the dendrimer provides a maximum concentration (Cmax) of cabazitaxel that is no more than 20% of the maximum concentration provided by administration of an equivalent dose of free cabazitaxel.

[0050] In some embodiments, administration of the dendrimer provides enhanced clinical efficacy compared to administration of an equivalent dose of free cabazitaxel.

[0051] In some embodiments, administration of the dendrimer results in reduced neutropenia, lymphopenia, anemia and / or thrombocytopenia compared to administration of an equivalent dose of free cabazitaxel.

[0052] In some embodiments, administration of the dendrimer provides a greater AUC of total cabazitaxel compared to direct administration of an equivalent dose of free cabazitaxel.

[0053] In some embodiments, administration of the dendrimer provides enhanced clinical efficacy compared to administration of an equivalent dose of free cabazitaxel.

[0054] In some embodiments, the course of dendrimer administered is 20 or 25 mg / m 2 provides enhanced clinical efficacy compared to three times weekly dosing of cabazitaxel.

[0055] In some embodiments, administration of the dendrimer results in reduced neutropenia, lymphopenia, anemia and / or thrombocytopenia compared to administration of an equivalent dose of free cabazitaxel.

[0056] In some embodiments, the administration of the dendrimer is at 20 or 25 mg / m 2 results in reduced neutropenia, lymphopenia, anemia, and / or thrombocytopenia compared with cabazitaxel given three times weekly.

[0057] In some embodiments, the subject matter of the present application provides drugs conjugated to dendrimers that exhibit an improved pharmacokinetic profile of at least one of improved therapeutic exposure, lower maximum concentration (Cmax) and / or increased area under the curve (AUC) compared to the unconjugated drug.

[0058] In a fifth aspect, there is provided a method of producing a dendrimer as defined herein, comprising the steps of: a) Cabazitaxel intermediates such as JPEG0007588065000013.jpg5363, wherein X is -OH or a leaving group, or X together with the attached C(O) group forms a carboxylate salt, i) a core unit (C); ii) a building unit, wherein each building unit (BU) is a lysine residue or an analogue thereof; Including, The core unit is covalently linked to two building units via amide bonds, each amide bond being formed between a nitrogen atom present in the core unit and a carbon atom of an acyl group present in a building unit; The dendrimer is a 5 generation building unit dendrimer; The building units of different generations are covalently linked to each other via amide bonds formed between a nitrogen atom present in one building unit and a carbon atom of an acyl group present in another building unit; The dendrimer comprises multiple second end groups (T2) each of which comprises a PEG group. and at least one-third of the nitrogen atoms present in the outer building units are each covalently bonded to a second end group; At least one-third of the nitrogen atoms present in the outer building units are unsubstituted and available for reaction with the first intermediate; a dendrimer intermediate, or a salt thereof; reacting under amide coupling conditions; or b) a PEG intermediate which is: JPEG0007588065000014.jpg2059, where PEG is a PEG-containing group; X is -OH or a leaving group, or X together with the attached C(O) group forms a carboxylate salt; i) a core unit (C); ii) a building unit, wherein each building unit (BU) is a lysine residue or an analogue thereof; Including, The core unit is covalently linked to two building units via amide bonds, each amide bond being formed between a nitrogen atom present in the core unit and a carbon atom of an acyl group present in a building unit; The dendrimer is a 5 generation building unit dendrimer; The building units of different generations are covalently linked to each other via amide bonds formed between a nitrogen atom present in one building unit and a carbon atom of an acyl group present in another building unit; The dendrimer comprises a plurality of first end groups (T1) each of which comprises a cabazitaxel residue covalently attached to a diglycolyl linker group. 1. A dendrimer intermediate further comprising: at least one-third of the nitrogen atoms present in the outer building units are each covalently bonded to a first end group; At least one-third of the nitrogen atoms present in the outer building units are unsubstituted; a dendrimer intermediate, or a salt thereof; reacting under amide coupling conditions; or c) a surface unit intermediate that is JPEG0007588065000015.jpg4374, where PEG group is a PEG-containing group, X is -OH or a leaving group, or X together with the attached C(O) group forms a carboxylate salt; i) a core unit (C); ii) a building unit, wherein each building unit (BU) is a lysine residue or an analogue thereof; Including, The core unit is covalently linked to two building units via amide bonds, each amide bond being formed between a nitrogen atom present in the core unit and a carbon atom of an acyl group present in a building unit; It is a fourth generation building unit dendrimer intermediate; The building units of different generations are covalently linked to each other via amide bonds formed between a nitrogen atom present in one building unit and a carbon atom of an acyl group present in another building unit; The nitrogen atoms present in the outer building units of the dendrimer intermediate are unsubstituted; a dendrimer intermediate, or a salt thereof; reacting under amide coupling conditions A method is provided that includes:

[0059] In a sixth aspect, the following dendrimer is provided: JPEG0007588065000016.jpg4362 (wherein X is -OH or a leaving group, or X together with the attached C(O) group forms a carboxylate salt) Intermediates for the preparation of

[0060] In a seventh aspect, the following dendrimer is provided: JPEG0007588065000017.jpg4983, where PEG is a PEG-containing group; X is -OH or a leaving group, or X together with the C(O) group to which it is attached forms a carboxylate salt. Intermediates for the preparation of

[0061] It will be appreciated that further aspects, embodiments and examples are described herein, which may include one or more of the above described embodiments or features. [Brief description of the drawings]

[0062] [Figure 1] FIG. 1 shows efficacy of a compound of the present disclosure (SPL9048) and comparator compounds (cabazitaxel, and SPL9005 - a comparator cabazitaxel-dendrimer compound) in SCID mice in a prostate cancer model study, as represented by change in mean tumor volume (TV) (mm3) over time. [Diagram 2] FIG. 1 shows the average weight change in SCID mice following administration of a compound of the disclosure (SPL9048) and comparative control compounds (cabazitaxel, and SPL9005 - comparative control cabazitaxel-dendrimer compound) over time in a prostate cancer model study. [Diagram 3] FIG. 1 shows the efficacy of a compound of the present disclosure (SPL9048) and a comparative compound (cabazitaxel) in SCID mice in a breast cancer tumor model study, as represented by the change in mean tumor volume (TV) (mm3) over time. [Figure 4] FIG. 1 shows the average body weight change in SCID mice following administration of a compound of the disclosure (SPL9048) and a comparative compound (cabazitaxel) over time in a breast cancer model study. [Diagram 5] FIG. 1 shows in vivo free cabazitaxel (release) concentration levels over time following administration of a compound of the present disclosure (SPL9048) and a comparative control cabazitaxel-dendrimer compound (SPL9005) to rats. [Figure 6] FIG. 1 shows the results of neutropenia toxicity study data for both male and female rats following administration of a compound of the disclosure (SPL9048) and a comparative compound (Jevtana® brand of cabazitaxel). [Figure 7]FIG. 1 shows the efficacy of a compound of the present disclosure (SPL9048) when administered alone and in combination with gemcitabine compared to comparators gemcitabine, Abraxane, and a combination of gemcitabine and Abraxane in female NOD-scid interleukin-2 receptor gamma chain null mice in a pancreatic cancer model study, as represented by the change in mean tumor volume (TV) (mm3) over time. [Figure 8] FIG. 1 shows levels (μg / L) of the prostate cancer biomarker PSA in patients with prostate cancer over time. [Figure 9] FIG. 1 shows levels of ovarian cancer biomarker CA-125 (μg / L) in patients with ovarian cancer over time. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0063] General definition Unless specifically defined otherwise, all technical and scientific terms used herein are intended to have the same meaning as commonly understood by one of ordinary skill in the art (e.g., chemistry, biochemistry, medicinal chemistry, polymer chemistry, etc.).

[0064] As used herein, the term "and / or", e.g., "X and / or Y", shall be understood to mean either "X and Y" or "X or Y" and shall be interpreted as explicitly endorsing both meanings or either meaning.

[0065] As used herein, unless stated to the contrary, the term about refers to + / - 20%, more preferably + / - 10% of the specified value.

[0066] As used herein, the singular forms "a," "an," and "the" include plural aspects unless the context clearly dictates otherwise.

[0067] Throughout this specification the word "comprise" or variations such as "comprises" or "comprising" are understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of other elements, integers or steps, or group of elements, integers or steps.

[0068] As used herein, the term "subject" refers to any organism susceptible to a disease or condition. In one embodiment, the disease or condition is cancer. For example, the subject can be a mammal, a primate, a livestock animal (e.g., sheep, cow, horse, pig), a companion animal (e.g., dog, cat), or an experimental animal (e.g., mouse, rabbit, rat, guinea pig, hamster). In one example, the subject is a mammal. In one embodiment, the subject is a human.

[0069] As used herein, the term "treating" includes alleviating symptoms associated with a particular disorder or condition, as well as eliminating said symptoms. For example, as used herein, the term "treating cancer" refers to alleviating symptoms associated with cancer, as well as eliminating said symptoms. In one embodiment, the term "treating cancer" refers to reducing cancerous tumor size. In one embodiment, the term "treating cancer" refers to increasing progression-free survival. As used herein, the term "progression-free survival" refers to the length of time during and after cancer treatment that a patient lives with the disease, i.e., cancer, but does not have a recurrence or increase in symptoms of the disease.

[0070] As used herein, the term "prevention" includes the prevention of a particular disorder or condition. For example, as used herein, the term "preventing cancer" refers to preventing the onset or persistence of symptoms associated with cancer. In one example, the term "preventing cancer" refers to slowing or stopping the progression of cancer. In one example, the term "preventing cancer" refers to slowing or preventing metastasis.

[0071] As will be appreciated by those skilled in the art, dendrimers will be administered in therapeutically effective amounts. As used herein, the term "therapeutically effective amount" refers to a dendrimer administered in an amount sufficient to alleviate or prevent to some extent one or more of the symptoms of the disorder or condition being treated. The result can be a reduction and / or alleviation of the signs, symptoms, or causes of a disease or condition, or other desired alteration of a biological system. In one embodiment, the term "therapeutically effective amount" refers to a dendrimer administered in an amount sufficient to cause a reduction in cancerous tumor size. In one embodiment, the term "therapeutically effective amount" refers to a dendrimer administered in an amount sufficient to cause an increase in progression-free survival. As used herein, the term "effective amount" refers to an amount of dendrimer effective to achieve a desired pharmacological effect or therapeutic improvement without undue adverse side effects, or with a reduced side effect profile. By way of example only, a therapeutically effective amount may be determined by routine experimentation, including, but not limited to, dose escalation clinical trials. The term "therapeutically effective amount" includes, for example, a prophylactically effective amount. In one embodiment, the prophylactically effective amount is an amount sufficient to prevent metastasis. It is understood that the "effective amount" or "therapeutically effective amount" may vary from subject to subject due to variations in the metabolism of the compound, and due to the subject's age, weight, or general condition, the condition being treated, the severity of the condition being treated, and the prescribing physician's judgment. Thus, it is not always possible to specify an exact "effective amount." However, the appropriate "effective amount" in each individual case can be determined by those skilled in the art using routine experimentation. When two or more therapeutic agents are used in combination, the "therapeutically effective amount" of each therapeutic agent can refer to the amount of the therapeutic agent that is therapeutically effective when used alone, or can refer to a reduced amount that is therapeutically effective when combined with one or more additional therapeutic agents.

[0072] As used herein, the term "alkyl" refers to straight chain (i.e., linear) or branched chain hydrocarbons (i.e., C 1~10Alkyl refers to alkyl groups having 1 to 6 carbon atoms (i.e., C 1 to C 2 ). Thus, alkyl moieties include moieties ranging in size from, for example, about 1 to about 6 carbon atoms or more, such as methyl, ethyl, n-propyl, isopropyl, and / or butyl, pentyl, hexyl, and higher isomers, unless expressly limited to a smaller group. In one example, an alkyl moiety has 1 to 10 carbon atoms (i.e., C 1~10 In another example, the alkyl moiety is of 2 to 4 carbon atoms, preferably 4 carbon atoms.

[0073] As used herein, the term "alkylene" refers to straight chain (i.e., linear) or branched chain hydrocarbons (i.e., C 1~10 Thus, alkylene moieties include, for example, -CH2-, -CH2CH2-, -CH2CH2CH2-, -CH2CH(CH3)-, -CH2CH2CH2CH2-, -CH2CH(CH3)CH2-, and the like.

[0074] Suitable salts of the dendrimers include those formed with organic or inorganic acids or bases. As used herein, the phrase "pharmaceutically acceptable salts" refers to pharmaceutically acceptable organic or inorganic salts. Exemplary acid addition salts include, but are not limited to, sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, and pamoate (i.e., 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)) salts. Exemplary base addition salts include, but are not limited to, ammonium salts, alkali metal salts, such as potassium and sodium salts, alkaline earth metal salts, such as calcium and magnesium salts, and salts with organic bases, such as dicyclohexylamine, N-methyl-D-glucamine, morpholine, thiomorpholine, piperidine, pyrrolidine, mono-, di-, or tri-lower alkylamines, such as ethyl-, tert-butyl-, diethyl-, diisopropyl-, triethyl-, tributyl-, or dimethyl-propylamine, or mono-, di-, or trihydroxy lower alkylamines, such as mono-, di-, or triethanolamine. Pharmaceutically acceptable salts may include the inclusion of another molecule, such as an acetate ion, a succinate ion, or other counterion. A counterion may be any organic or inorganic moiety that stabilizes the charge of the parent compound. In addition, a pharma-ceutically acceptable salt may have more than one charged atom in its structure. Examples in which multiple charged atoms are part of a pharma-ceutically acceptable salt may have multiple counterions. Hence, a pharma- ceutically acceptable salt can have one or more charged atoms and / or one or more counter ion.It is also understood that non-pharmacologically acceptable salts also fall within the scope of the disclosure, since they may be useful as intermediates in the preparation of pharma-ceutically acceptable salts, or may be useful during storage or transportation.

[0075] Those skilled in the art of organic chemistry and / or medicinal chemistry will understand that many organic compounds can form complexes with solvents in which they react or in which they are precipitated or crystallized. These complexes are known as "solvates." For example, a complex with water is known as a "hydrate." As used herein, the phrase "a pharmaceutically acceptable solvate" or "solvate" refers to an association of one or more solvent molecules with a compound of the present disclosure. Examples of solvents that form pharmaceutically acceptable solvates include, but are not limited to, water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, and ethanolamine.

[0076] As used herein, the term "dendrimer" refers to a molecule comprising a core and dendrons attached to the core. Each dendron is composed of generations of branched building units resulting in a branched structure with an increasing number of branches at each generation of building units. "Dendrimers" including drug-dendrimer conjugates may include pharma- ceutically acceptable salts or solvates as defined above.

[0077] As used herein, the term "building unit" refers to a branched molecule that is a lysine residue or analogue thereof, having three functional groups, one for attachment to the core or previous generation of building unit, and at least two functional groups for attachment to the next generation of building units or for forming the surface of the dendrimer molecule.

[0078] As used herein, the term "bonded" refers to a connection between chemical moieties by a covalent bond. As used herein, the term "covalent bond" refers to a chemical bond formed by the sharing of one or more electrons, particularly electron pairs, between atoms. The term "covalent bonding" is used interchangeably with the term "covalent attachment."

[0079] As used herein, the term "solubilizing excipient" refers to a formulation additive used to solubilize insoluble or poorly soluble drugs in aqueous formulations. Examples include polyethoxylated castor oil, including Cremophor EL, Cremophor RH 40 and Cremophor RH 60, D-α-tocopherol-polyethylene glycol 1000 succinate, polysorbate 20, polysorbate 80, solutol HS 15, sorbitan monooleate, poloxamer 407, Labrasol, and other surfactants.

[0080] Jevtana® is manufactured by Sanofi (France) and is an example of free cabazitaxel for comparison with dendrimers. Pharmacokinetic data for Jevtana® has been published (see, for example, Mita AC, Denis LJ, Rowinsky EK, et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res. 2009; 15(2): 723-730).

[0081] For Mita, 25 mg / m 2Dose correlated with a Cmax of 535 ± 305 mcg / L and an AUC concentration of 642 ± 320 mcg / L / hour. A triphasic model was used to explain the reduced plasma concentrations of the drug. Plasma pharmacokinetic activity was characterized by a rapid initial elimination phase (mean terminal half-life [t1 / 2] = 2.6 ± 1.4 min), followed by an intermediate elimination phase (mean t1 / 2 = 1.3 ± 0.6 hr), and a prolonged terminal elimination phase (mean t1 / 2 = 77.3 ± 45.5 hr). Approximately 80% of the dose was eliminated within 2 weeks. The volume of distribution at steady state was large and highly variable (2,034 ± 1,495 L / m2).

[0082] The primary dose-limiting toxicity in this study was hematologic myelosuppression (i.e., neutropenia). One patient (4%) experienced prolonged grade 4 neutropenia and a second patient (4%) experienced febrile neutropenia, both at the 25 mg / m2 dose. Nonhematologic toxicities also occurred. Two patients (8%) experienced flushing, dizziness, and chest tightness, identified as grade 1 hypersensitivity reactions. Other nonhematologic toxicities included diarrhea (14 patients; 56%), nausea (10 patients; 40%), fatigue (9 patients; 36%), neurotoxicity (9 patients; 36%), and vomiting (4 patients; 16%).

[0083] In the phase 3 TROPIC study in patients with metastatic prostate cancer (n=67), the mean Cmax was 226 ng / mL (coefficient of variation, CV 107%) and was reached at the end of the 1-hour infusion (Tmax). The mean AUC was 991 ng.hr / mL (CV: 34%). Neutropenia (all grades) occurred in 94% of cabazitaxel patients, and grade 3 or 4 febrile neutropenia occurred in 8% of cabazitaxel patients. In the TROPIC registration trial of Jevtana, after 1-hour IV administration of 25 mg / m2 cabazitaxel (de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet. 2010;376(9747):1147-1154). Dendrimer

[0084] In a first aspect, i) a core unit (C); ii) a building unit, wherein each building unit (BU) is a lysine residue or an analogue thereof; Including, The core unit is covalently linked to two building units via amide bonds, each amide bond being formed between a nitrogen atom present in the core unit and a carbon atom of an acyl group present in a building unit; It is a 5th generation building unit dendrimer; The building units of different generations are covalently linked to each other via amide bonds formed between a nitrogen atom present in one building unit and a carbon atom of an acyl group present in another building unit; iii) a plurality of first terminal groups (T1), each of which comprises a cabazitaxel residue covalently attached to a diglycolyl linker group; iv) a plurality of second end groups (T2), each of which comprises a PEG group; A dendrimer further comprising at least one-third of the nitrogen atoms present in the outer building units are each covalently bonded to a first end group; At least one-third of the nitrogen atoms in the outer building units are each covalently bonded to a second end group. A dendrimer, or a pharma- ceutically acceptable salt thereof, is provided.

[0085] The core unit (C) of the dendrimer is covalently linked to two building units via amide bonds, each amide bond being formed between a nitrogen atom present in the core unit and a carbon atom of an acyl group present in the building unit. Thus, the core unit can be formed, for example, from a core unit precursor that contains two amino groups. Any suitable diamino-containing molecule can be used as the core unit precursor. In some embodiments, the core unit is: For example, it may be formed from the following core unit precursor, which has two reactive (amino) nitrogens: JPEG0007588065000019.jpg3159

[0086] The building units (BU) are lysine residues or analogues thereof and may be formed from suitable building unit precursors, such as lysine or lysine analogues containing suitable protecting groups. The lysine analogues have two amino nitrogen atoms for attachment to the next generation of building units and an acyl group for attachment to the previous generation of building units or core. Examples of suitable building units include: JPEG0007588065000020.jpg2144, JPEG0007588065000021.jpg2155, JPEG0007588065000022.jpg3048, JPEG0007588065000023.jpg2540, and JPEG0007588065000024.jpg2549 (wherein the acyl group of each building unit provides a covalent attachment point for bonding to the core or a previous generation building unit; each nitrogen atom provides a covalent attachment point for covalently bonding to a subsequent generation building unit, the first terminal group or the second terminal group). In some preferred embodiments, the building units are each: JPEG0007588065000025.jpg2145; where the acyl group of each building unit provides a covalent attachment point for bonding to the core or a previous generation building unit; and each nitrogen atom provides a covalent attachment point for covalently bonding to a subsequent generation building unit, the first terminal group or the second terminal group.

[0087] In some preferred embodiments, the building units are each: JPEG0007588065000026.jpg2552; where the acyl group of each building unit provides a covalent attachment point for bonding to the core or a previous generation building unit; and each nitrogen atom provides a covalent attachment point for covalently bonding to a subsequent generation building unit, the first terminal group or the second terminal group.

[0088] The outermost generation of the building unit (BU outer ) may be formed by the lysine or lysine analogue building units used in the other generations of building units (BU) described above. The outermost generation of building units (BU outer ) is the generation of the building unit that is the outermost from the dendrimer core, i.e., the outermost generation of the building unit (BU outer ) does not have further generations of building units attached to it.

[0089] It will be understood that the dendrons of the dendrimer can be synthesized, for example, through the attachment of building units (BU) as appropriate, up to the required number of generations. In some embodiments, each generation of building units (BU) can be formed of the same building units, for example, all of the building units of a generation can be lysine building units. In some other embodiments, one or more generations of building units can be formed of building units that are different from other generations of building units.

[0090] The dendrimer is a generation 5 building unit dendrimer. A generation 5 building unit dendrimer is a dendrimer having a structure that includes five building units that are covalently bonded to one another, for example, when the building unit is lysine, it may include the following substructure: JPEG0007588065000027.jpg4167.

[0091] In some embodiments, the dendrimer has 5 complete generations of building units. In the case of a core with two reactive amine groups, such a dendrimer would contain 62 building units (i.e., core unit + 2BU + 4BU + 8BU + 16BU + 32BU). However, it will be understood that due to the nature of the synthetic method of producing the dendrimer, one or more reactions carried out to produce the dendrimer may not be fully completed. Thus, in some embodiments, the dendrimer may contain an incomplete generation of building units. For example, a population of dendrimers may be obtained in which the dendrimers have a distribution of the number of building units per dendrimer. In some embodiments, a population of dendrimers is obtained in which the average number of building units per dendrimer is at least 55, or at least 56, or at least 57, or at least 58, or at least 59, or at least 60. In some embodiments, a population of dendrimers is obtained in which at least 60%, at least 70%, at least 80%, at least 90%, or at least 95% of the dendrimers have 55 or more building units. In some embodiments, a population of dendrimers is obtained in which at least 60%, at least 70%, at least 80%, at least 90%, or at least 95% of the dendrimers have 60 or more building units.

[0092] Each reactive (amino) group of the core represents a conjugation site for a dendron containing one or more generations of building units. The core has two reactive (amino) groups and two dendrons for attaching several generations of building units.

[0093] In some embodiments, each generation of building units within each dendron (X) may be represented by the formula [BU]2(b-1), where b is the generation number. A dendron (X) having five complete generations of building units is represented by the formula [BU]1-[BU]2-[BU]4-[BU]8-[BU] 16It is expressed as:

[0094] The dendrimer comprises a plurality of first terminal groups (T1) each comprising a cabazitaxel residue covalently attached to a diglycolyl linker group. Each first terminal group (T1) preferably comprises one of the following: JPEG0007588065000028.jpg4857, That is, a cabazitaxel residue covalently attached to the diglycolyl linker via an ester bond formed between an oxygen atom present as part of the cabazitaxel side chain and a carbon atom of an acyl group present as part of the diglycolyl linker. The other acyl group of the diglycolyl linker forms an amide bond with a nitrogen atom present in an outer building unit. In such an embodiment, the cabazitaxel residue is: JPEG0007588065000029.jpg4768.

[0095] Upon in vivo administration, the dendrimers typically release cabazitaxel, namely: JPEG0007588065000030.jpg4972.

[0096] The dendrimer comprises a plurality of second terminal groups (T2), each of which comprises a PEG group. The second terminal group T2 is a pharmacokinetic modifier. A pharmacokinetic modifier is an agent that can modify or modulate the pharmacokinetic profile of the dendrimer or the pharmacokinetically active agent (i.e., cabazitaxel) that it is delivering. A pharmacokinetic modifier may modulate the absorption, distribution, metabolism, excretion and / or toxicity of the dendrimer of the pharmacokinetic agent. A pharmacokinetic modifier (T2) may affect the release rate of the pharmacokinetic agent by slowing or increasing the rate at which the active agent is released from the dendrimer by either chemical (e.g., hydrolysis) or enzymatic degradation pathways. A pharmacokinetic modifier (T2) may change the solubility profile of the dendrimer, increasing or decreasing the solubility of the dendrimer in a pharmacologic acceptable carrier. A pharmacokinetic modifier (T2) may assist the dendrimer in delivering the pharmacokinetic agent to a specific tissue (e.g., tumor). The pharmacokinetic modifier (T2) may extend the half-life of the pharmacokinetically active agent by decreasing the clearance of the dendrimer.

[0097] A PEG group is a polyethylene glycol group, i.e., a group that contains repeating units of the formula -CH2CHO-. The PEG material used to prepare the dendrimers of the present disclosure typically comprises a mixture of PEGs with some variation in molecular weight (i.e., ±10%), and thus the molecular weight specified is typically an approximation of the average molecular weight of the PEG composition. For example, "PEG 約2100 The term "polyethylene glycol" refers to polyethylene glycol (i.e., PEG) having an average molecular weight of approximately 2100 Daltons, i.e., ±approximately 10%. 1900 ~PEG 2300) refers to the molecular weight (MW) of a polymer. Three methods are commonly used to calculate MW average: number average, weight average, and z-average molecular weight. As used herein, the phrase "molecular weight" is intended to refer to a weight average molecular weight that can be measured using techniques well known in the art, including, but not limited to, NMR, mass spectrometry, matrix-assisted laser desorption / ionization time-of-flight (MALDI-TOF), gel permeation chromatography or other liquid chromatography techniques, light scattering techniques, ultracentrifugation, and viscometry.

[0098] In some embodiments, the second end group comprises a PEG group having an average molecular weight of about 200-5000 daltons. In some embodiments, the second end group comprises a PEG group having an average molecular weight of at least 750 daltons. In some embodiments, the second end group comprises a PEG group having an average molecular weight in the range of 1000-2500 daltons. In some embodiments, the second end group comprises a PEG group having an average molecular weight in the range of 1900-2300 daltons. In some embodiments, the second end group comprises a PEG group having an average molecular weight in the range of 2000-2200 daltons. In some embodiments, the second end group comprises a PEG group having an average molecular weight of about 2100 daltons.

[0099] In some embodiments, the PEG groups have a polydispersity index (PDI) between about 1.00 and about 1.50, about 1.00 and about 1.25, or about 1.00 and about 1.10. In some embodiments, the PEG groups have a polydispersity index (PDI) of about 1.05. The term "polydispersity index" refers to a measure of the distribution of molecular masses in a given polymer sample. The polydispersity index (PDI) is a function of the weight average molecular weight (M w ) to the number average molecular weight (M n The polydispersity index (PDI) is equal to the mass of the individual molecules divided by the molecular weight (Mn) and indicates the distribution of the masses of the individual molecules within a batch of polymer. The polydispersity index (PDI) can have a value greater than or equal to 1, but as a polymer approaches uniform length and average molecular weight, the PDI approaches 1.

[0100] In some embodiments, the PEG group is a methoxy-terminated PEG.

[0101] The PEG group may be attached to the outer building unit via any suitable means. In some embodiments, a PEG linking group is used to attach the PEG group to the outer building unit. In some embodiments, the second terminal groups each comprise a PEG group covalently attached to the PEG linking group via an ether bond formed between a carbon atom present in the PEG group and an oxygen atom present in the PEG linking group (L1), and each second terminal group is covalently attached to the building unit via an amide bond formed between a nitrogen atom present in the building unit and a carbon atom of an acyl group present in the PEG linking group. In some embodiments, the second terminal groups each are JPEG0007588065000031.jpg2159, where the PEG group is a methoxy-terminated PEG having an average molecular weight in the range of about 1750-2500 daltons.

[0102] In the dendrimers of the present disclosure, at least one-third of the nitrogen atoms present in the exterior building units are each covalently bonded to a first terminal group; At least one-third of the nitrogen atoms present in the outer building units are each covalently bonded to a second end group.

[0103] In some embodiments, dendrimers have a controlled stoichiometry and / or topology. For example, dendrimers are typically manufactured using synthetic methods that allow for a high degree of control over the number and arrangement of first and second end groups present on the dendrimer. In some embodiments, each functionalized exterior building unit comprises one first end group and one second end group. In some embodiments, dendrimers comprise surface units that comprise exterior building units attached to a first end group and a second end group, and the surface units have the following structure: JPEG0007588065000032.jpg4374, where the PEG group is a methoxy-terminated PEG having an average molecular weight in the range of about 1750-2500 Daltons. In some embodiments, the dendrimer has 28-32 surface units. In some embodiments, the dendrimer has 30-32 surface units.

[0104] In some embodiments, at least 40% of the nitrogen atoms present in the outer building units are each covalently bonded to a first terminal group. In some embodiments, at least 45% of the nitrogen atoms present in the outer building units are each covalently bonded to a first terminal group. In some embodiments, about 50% of the nitrogen atoms present in the outer building units are each covalently bonded to a first terminal group.

[0105] In some embodiments, at least 40% of the nitrogen atoms present in the outer building units are each covalently bonded to the second terminal group. In some embodiments, at least 45% of the nitrogen atoms present in the outer building units are each covalently bonded to the second terminal group. In some embodiments, about 50% of the nitrogen atoms present in the outer building units are each covalently bonded to the second terminal group.

[0106] In some embodiments, at least 40% of the nitrogen atoms present in the outer building units are covalently bonded to the first end group, respectively; at least 40% of the nitrogen atoms present in the outer building units are covalently bonded to the second end group, respectively. In some embodiments, at least 45% of the nitrogen atoms present in the outer building units are covalently bonded to the first end group, respectively; at least 45% of the nitrogen atoms present in the outer building units are covalently bonded to the second end group, respectively. In some embodiments, about 50% of the nitrogen atoms present in the outer building units are covalently bonded to the first end group, respectively; and about 50% of the nitrogen atoms present in the outer building units are covalently bonded to the second end group, respectively.

[0107] In some embodiments, five generations of building units are complete generations, with the outer generation of building units providing 64 nitrogen atoms for covalent attachment to a first terminal group or a second terminal, with 26-32 first terminal groups covalently attached to one of said nitrogen atoms, and 28-32 second terminal groups each covalently attached to one of said nitrogen atoms. In some embodiments, 28-32 first terminal groups each covalently attached to one of said nitrogen atoms. In some embodiments, 29-31 first terminal groups each covalently attached to one of said nitrogen atoms.

[0108] In some embodiments, the cabazitaxel residues comprise at least 20% w / w of the dendrimer, at least 22% w / w of the dendrimer, or at least 24% w / w of the dendrimer. In some embodiments, the cabazitaxel residues comprise up to 30% w / w of the dendrimer, up to 28% w / w of the dendrimer, or up to 26% w / w of the dendrimer. In some embodiments, the cabazitaxel residues comprise a w / w % of the dendrimer ranging from 20% w / w to 30% w / w, or from 23% w / w to 28% w / w, or from 24% w / w to 26% w / w. The w / w % of the dendrimer that are cabazitaxel residues may be determined by any suitable means. In some embodiments, the w / w % of the dendrimer that are cabazitaxel residues is: 1 It can be determined by 1 H NMR.

[0109] In some embodiments, no more than a quarter of the nitrogen atoms present in the outer generations of the building units are unsubstituted. In some embodiments, no more than a fifth of the nitrogen atoms present in the outer generations of the building units are unsubstituted. In some embodiments, no more than a sixth of the nitrogen atoms present in the outer generations of the building units are unsubstituted. In some embodiments, no more than an eighth of the nitrogen atoms present in the outer generations of the building units are unsubstituted. In some embodiments, no more than a tenth of the nitrogen atoms present in the outer generations of the building units are unsubstituted.

[0110] In some embodiments, no more than 20 nitrogen atoms present in the outer generation of the building units are unsubstituted. In some embodiments, no more than 10 nitrogen atoms present in the outer generation of the building units are unsubstituted. In some embodiments, no more than 5 nitrogen atoms present in the outer generation of the building units are unsubstituted. In some embodiments, no more than 3 nitrogen atoms present in the outer generation of the building units are unsubstituted. In some embodiments, no more than 2 nitrogen atoms present in the outer generation of the building units are unsubstituted. In some embodiments, no more than 1 nitrogen atom present in the outer generation of the building units is unsubstituted. In some embodiments, substantially all nitrogen atoms present in the outer generation of the building units are substituted.

[0111] In some embodiments, the dendrimer is: JPEG0007588065000033.jpg6274 (wherein T1' represents the first terminal group JPEG0007588065000034.jpg5365 or T1' represents H, and T1' is less than 5 H; T2' represents the second end group JPEG0007588065000035.jpg2058, where the PEG group is a methoxy-terminated PEG having an average molecular weight in the range of about 1750 to 2500 daltons, or T2' represents H and less than five of T2' are H.

[0112] In some embodiments, the dendrimer has a molecular weight in the range of 50 to 300 kDa. In some embodiments, the dendrimer has a molecular weight in the range of 75 to 200 kDa. In one example, the dendrimer has a molecular weight in the range of 90 to 150 kDa.

[0113] In some embodiments, the in vitro half-life of cabazitaxel release from the dendrimer in PBS (phosphate buffered saline) at pH 7.4 and 37° C. ranges from 20 to 100 hours. In some embodiments, the in vitro half-life of cabazitaxel release from the dendrimer in PBS at pH 7.4 and 37° C. ranges from 24 to 60 hours. In some embodiments, the in vitro half-life of cabazitaxel release from the dendrimer in PBS at pH 7.4 and 37° C. ranges from 30 to 60 hours. In some embodiments, the in vitro half-life of cabazitaxel release from the dendrimer in PBS at pH 7.4 and 37° C. ranges from 30 to 50 hours. composition

[0114] In some embodiments, the dendrimer is provided as a composition, preferably a pharmaceutical composition.

[0115] It will be appreciated that as a result of the nature of the synthetic methods for producing dendrimers, there may be some variation in molecular composition between the dendrimers present in a given composition. For example, as noted above, one or more of the synthetic steps used to produce a dendrimer may not proceed to full completion, resulting in the presence of dendrimers that do not all contain the same number of first or second end groups, or that contain incomplete generations of building units.

[0116] Thus, there is provided a composition comprising a plurality of dendrimers, or a pharma- ceutically acceptable salt thereof, wherein the dendrimer is as defined herein, the average number of first end groups per dendrimer in the composition is in the range of 24 to 32; the average number of second end groups per dendrimer in the composition is in the range of 24 to 32; Compositions are provided. In some embodiments, the average number of first end groups per dendrimer is in the range of 26-32 and the average number of second end groups per dendrimer is in the range of 28-32. In some embodiments, the average number of first end groups per dendrimer is in the range of 28-32, or in the range of 29-31. In some embodiments, the average number of second end groups per dendrimer is in the range of 29-31.

[0117] In some embodiments, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95% of the dendrimers comprise at least 24 first end groups. In some embodiments, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95% of the dendrimers comprise at least 26 first end groups. In some embodiments, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95% of the dendrimers comprise at least 28 first end groups.

[0118] In some embodiments, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95% of the dendrimers comprise at least 28 second end groups. In some embodiments, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95% of the dendrimers comprise at least 29 second end groups.

[0119] In some embodiments, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95% of the dendrimers comprise at least 24 first end groups and at least 28 second end groups. In some embodiments, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95% of the dendrimers comprise at least 26 first end groups and at least 29 second end groups.

[0120] In some embodiments, a composition comprising a plurality of dendrimers or pharma- ceutically acceptable salts thereof comprises cabazitaxel residues in an amount of at least 20% w / w, at least 22% w / w, or at least 24% w / w of the dendrimer present in the composition. In some embodiments, a composition comprising a plurality of dendrimers or pharma- ceutically acceptable salts thereof comprises cabazitaxel residues in an amount of up to 30% w / w of the dendrimer, up to 28% w / w of the dendrimer, or up to 26% w / w of the dendrimer. In some embodiments, a composition comprising a plurality of dendrimers or pharma- ceutically acceptable salts thereof comprises cabazitaxel residues in an amount ranging from 20% w / w to 30% w / w, or from 23% w / w to 28% w / w, or from 24% w / w to 26% w / w. The w / w% of the dendrimer that is cabazitaxel residues may be determined by any suitable means. In some embodiments, the w / w% of the dendrimer that is cabazitaxel residues is 1 It can be determined by 1 H NMR.

[0121] The present disclosure also provides pharmaceutical compositions for both veterinary and human medical use, comprising a dendrimer of the present disclosure or a pharma- ceutically acceptable salt thereof in combination with one or more pharma- ceutically acceptable carriers, and optionally any other therapeutic ingredients, stabilizers, and the like. The carrier must be pharma- ceutically acceptable in the sense of being compatible with the other ingredients of the formulation and not unduly harmful to the recipient thereof. In some embodiments, the composition is a pharmaceutical composition, and the composition comprises a pharma- ceutical acceptable excipient. The compositions of the present disclosure may also include polymeric excipients / additives or carriers, for example, polyvinylpyrrolidone, derivatized celluloses such as hydroxymethylcellulose, hydroxyethylcellulose, and hydroxypropylmethylcellulose, Ficoll (polymeric sugars), hydroxyethyl starch (HES), dextrates (e.g., cyclodextrins such as 2-hydroxypropyl-β-cyclodextrin and sulfobutylether-β-cyclodextrin), polyethylene glycol, and pectin. The compositions may further include diluents, buffers, citrates, trehalose, binders, disintegrants, thickeners, lubricants, preservatives (including antioxidants), inorganic salts (e.g., sodium chloride), antimicrobial agents (e.g., benzalkonium chloride), sweeteners, antistatic agents, sorbitan esters, lipids (e.g., phospholipids such as lecithin and other phosphatidylcholines, phosphatidylethanolamines, fatty acids and fatty esters, steroids (e.g., cholesterol)), and chelating agents (e.g., EDTA, zinc and other such suitable cations).Other pharmaceutical excipients and / or additives suitable for use in the compositions according to the present disclosure are listed in "Remington: The Science & Practice of Pharmacy", 19th ed., Williams & Williams, (1995) and "Physician's Desk Reference", 52nd ed., Medical Economics, Montvale, NJ (1998) and "Handbook of Pharmaceutical Excipients", Third Ed., Ed. A. H. Kibbe, Pharmaceutical Press, 2000.

[0122] In some embodiments, the composition is a solid composition suitable for reconstitution with a diluent. For example, the composition may be in the form of a powder or granules. Such a composition may be advantageous for transport and / or storage of the dendrimer prior to administration, for example, helping to provide stability of the dendrimer.

[0123] In some embodiments, a stable composition is one in which the cabazitaxel release rate from the dendrimer is less than 1%, less than 0.5%, less than 0.2%, or less than 0.1% of total cabazitaxel over a period of 4 hours at room temperature, e.g., 25°C.

[0124] Excipients used with such solid compositions may include, for example, buffers or other pH control agents. pH control agents may be useful, for example, to protect and / or maintain the chemical stability of the dendrimer, either in the solid composition itself, or in the subsequent reconstituted composition when the solid composition is mixed with a diluent. In some embodiments, an acid is used in the solid composition that can provide a pH of less than 6, or can provide a pH in the range of less than 5, or can provide a pH in the range of 3.5-5.5, or can provide a pH in the range of 4-5, or can provide a pH of about 4.5, after reconstitution with a diluent. In some embodiments, the reconstituted composition has a pH in the range of less than 5, in the range of 3.5-5.5, in the range of 4-5, or about 4.5, after reconstitution with a diluent. In some embodiments, an acid having an acidic group with a pKa in the range of 4-5 is used. In some embodiments, an acid such as citric acid is included in the composition.

[0125] In some embodiments, the solid composition comprises a bulking agent, such as a non-reducing sugar. In some embodiments, the sugar is a disaccharide. In some embodiments, the sugar is trehalose, mannitol, sorbitol, or lactose.

[0126] In some embodiments, the solid composition comprises a sugar and an acid, and the composition is for reconstitution with a diluent, hi some embodiments, the composition comprises trehalose and citric acid.

[0127] In some embodiments, the composition comprises a dendrimer and a sugar (preferably trehalose) in a weight ratio ranging from 1:1 to 1:3, or about 1:2. In some embodiments, the composition comprises a dendrimer and an acid (preferably citric acid) in a weight ratio ranging from 1:0.5 to 1:2, or about 1:1, or about 1:0.96. In some embodiments, the weight ratio of dendrimer:sugar:acid is about 100:200:96. In some embodiments, the weight ratio of dendrimer:sugar:acid in the composition is about 100:200:96, and the composition comprises cabazitaxel residues in an amount of 23% w / w to 28% w / w of the dendrimer.

[0128] In some embodiments, the composition is produced by lyophilization, i.e., the composition is a lyophilizate. In some embodiments, the composition is a solid lyophilizate comprising a dendrimer or a pharma- ceutically acceptable salt thereof, a sugar, and an acid. In some embodiments, the composition is a solid lyophilizate comprising a dendrimer or a pharma- ceutically acceptable salt thereof, trehalose, and citric acid.

[0129] In some embodiments, the composition is a liquid composition, e.g., a reconstituted composition suitable for administration by injection or infusion.For example, the composition can be a reconstituted composition prepared by mixing the solid composition discussed above with a diluent such as saline or WFI (water for injection).

[0130] In some embodiments, the liquid composition is a reconstituted composition that is sufficiently stable at ambient conditions (e.g., about 25° C.) for use for up to 2 hours, up to 4 hours, up to 6 hours, up to 12 hours, or up to 24 hours, or up to 48 hours, or up to 1 week after reconstitution. In some embodiments, the liquid composition is a reconstituted composition that is sufficiently stable under refrigeration (e.g., about 4° C.) for use for up to 2 hours, up to 4 hours, up to 6 hours, up to 12 hours, or up to 24 hours, or up to 48 hours, or up to 1 week after reconstitution. In some embodiments, the liquid composition is a reconstituted composition that is sufficiently stable when protected from light for use for up to 2 hours, up to 4 hours, up to 6 hours, up to 12 hours, or up to 24 hours, or up to 48 hours, or up to 1 week after reconstitution.

[0131] After reconstitution and prior to transfer to an infusion bag (saline), data was found to show that the reconstituted solution according to the present invention is stable (less than 0.1% cabazitaxel release) for at least 4 hours at room temperature (25±5° C.).

[0132] In some embodiments, the liquid composition is one in which the release rate of cabazitaxel from the dendrimer when present in the composition is less than 1%, less than 0.5%, less than 0.2%, or less than 0.1% of the total cabazitaxel over a period of 4 hours at room temperature, e.g., 25°C.

[0133] In some embodiments, the liquid composition is a reconstituted composition present in an infusion bag, hi some embodiments, the liquid composition is a reconstituted composition present in a syringe.

[0134] It will be appreciated that the above compositions may be utilized with drug-dendrimer conjugates other than those described in the first aspect, for example other drug-dendrimer conjugates in which the pharma- ceutically active agent is linked through a hydroxyl group to the dendrimer via a diglycolyl linker.

[0135] Thus, also provided herein is a pharmaceutical composition comprising: a) a dendrimer comprising a core unit, building units, a plurality of first end groups (T1) each comprising a residue of a pharmacoactive agent comprising a hydroxyl group covalently attached to a diglycolyl linker group, and a plurality of second end groups (T2) each comprising a pharmacokinetic modifier, wherein the first end group and the second end group are covalently attached to an outer building unit; and b) an acid. In some embodiments, the pharmacokinetic modifier is a tumor agent, e.g., a taxane, such as docetaxel or cabazitaxel. In some embodiments, the pharmacokinetic modifier comprises a PEG or PEOX group. In some embodiments, the pharmacokinetic modifier comprises a PEG group. In some embodiments, the core is a BHALys group. In some embodiments, the building unit is a lysine residue or an analog thereof. In some embodiments, the dendrimer is a 5 generation building unit dendrimer. In some embodiments, the acid is citric acid. In some embodiments, the composition comprises c) a sugar, such as a disaccharide, such as trehalose. In some embodiments, the composition is a solid composition. In some embodiments, the composition is produced by lyophilization, i.e., the composition is a solid lyophilizate. In some embodiments, the composition is for reconstitution with a diluent. In some embodiments, the composition is a liquid composition, such as a reconstituted composition suitable for administration by injection or infusion. For example, the composition can be a reconstituted composition produced by mixing a solid composition discussed above with a diluent such as saline or WFI (water for injection). The dendrimers of the present disclosure can be provided in compositions including compositions suitable for inhalation into the lungs by aerosol or parenteral (including intraperitoneal, intravenous, subcutaneous or intramuscular injection) administration. The compositions are conveniently provided in unit dosage form and can be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the dendrimer into association with a carrier which constitutes one or more accessory ingredients.Generally, the compositions are prepared by associating the dendrimer with a liquid carrier to form a solution or suspension, or by associating the dendrimer with suitable composition components to form a solid, optionally particulate, product, and then, if necessary, shaping the product into the desired delivery form. Solid compositions of the present disclosure, when particulate, will typically include particles ranging in size from about 1 nanometer to about 500 microns. Generally, for solid compositions intended for intravenous administration, the particles will typically range in diameter from about 1 nm to about 10 microns. The composition may include dendrimers of the present disclosure that are nanoparticles having a particle size of less than 1000 nm, such as 5-1000 nm, particularly 5-500 nm, more particularly 5-400 nm, such as 5-50 nm, and particularly 5-20 nm. In one example, the composition includes dendrimers having an average size of 5-20 nm. In some embodiments, the dendrimers are polydispersed in the composition with a PDI of 1.01-1.8, particularly 1.01-1.5, and more particularly 1.01-1.2. In one example, the dendrimers are monodisperse in the composition.

[0136] In some preferred embodiments, the composition is for parenteral delivery. For example, in one embodiment, the composition may be a sterile, lyophilized composition suitable for reconstitution in an aqueous vehicle prior to injection.

[0137] In one embodiment, compositions suitable for parenteral administration conveniently comprise a sterile aqueous preparation of the dendrimer, which can be adjusted to be, for example, isotonic with the blood of the recipient.

[0138] Pharmaceutical compositions suitable for administration as an aerosol by inhalation are also provided. These compositions include a solution or suspension of the desired dendrimer or its salt. The desired composition can be placed in a small chamber and nebulized. Nebulization can be achieved by compressed air or ultrasonic energy to form a plurality of liquid droplets or solid particles including the dendrimer or its salt.

[0139] In some embodiments, the composition may be formulated for administration as an infusion. In some embodiments, the composition may be formulated for administration as a bolus. In some embodiments, the composition is formulated for administration as an infusion over a period of up to 30 minutes, or is formulated for administration as a bolus over a period of up to 5 minutes.

[0140] As discussed below, the dendrimers of the present disclosure may be administered in combination with, for example, one or more additional pharma- ceutically active agents. Thus, in some embodiments, a composition comprises a dendrimer as defined herein, or a pharma- ceutically acceptable salt thereof, one or more pharma- ceutically acceptable carriers, and one or more additional pharma- ceutically active agents, such as additional tumor agents, cytotoxic small molecules, checkpoint inhibitors, antibody therapy. In some embodiments, a composition comprises a dendrimer as defined herein, or a pharma- ceutically acceptable salt thereof, and an additional tumor agent, such as gemcitabine. The dendrimers of the present disclosure may be administered in combination with other chemotherapeutic agents, as well as other drugs, such as corticosteroids, antihistamines, analgesics, and drugs that aid in recovery or protect against hematologic toxicity, e.g., cytokines.

[0141] In some embodiments, the composition is for parenteral injection as part of a chemotherapy regimen. In these embodiments, the composition can be substantially free or completely free of solubilizing excipients, for example, particularly solubilizing excipients such as polyethoxylated castor oil (such as those sold under the trade names Cremophor® or Kolliphor®) or polyethoxylated sorbitan monooleate (such as those sold under the trade name Polysorbate 80®). Solubilizing excipients are additives that aid in the dissolution of the dendrimer in one or more solvents. In one embodiment, the composition is substantially free or completely free of polyethoxylated castor oil (such as those sold under the trade names Cremophor® or Kolliphor®) and polyethoxylated sorbitan monooleate (such as Polysorbate 80®). In one embodiment, the composition is substantially or completely free of solubilizing excipients. By avoiding the use of solubilizing excipients, the dendrimer compositions are less likely to cause side effects such as acute or delayed hypersensitivity, including life-threatening anaphylaxis and / or severe fluid retention, and / or eliminate the need for steroid pretreatment. How to use

[0142] The dendrimers of the present disclosure may be used to treat or prevent any disease, disorder or condition for which an unmodified pharma- ceutical active agent can be used to treat or prevent. Accordingly, there is also provided a dendrimer or pharmaceutical composition described herein for use in therapy.

[0143] In some embodiments, the dendrimer is used in a method of treating or preventing cancer, for example to inhibit tumor growth. In some embodiments, the dendrimer is for use in treating cancer. Also provided is a method of treating cancer, comprising administering a therapeutically effective amount of a dendrimer to a subject in need thereof. Also provided is the use of a dendrimer as defined herein or a composition as defined herein in the manufacture of a medicament for treating cancer.

[0144] In some embodiments, the cancer is a solid tumor. The cancer can be a primary tumor or a metastatic tumor. In some embodiments, the cancer is a primary tumor. In some embodiments, the cancer is a metastatic tumor.

[0145] In some embodiments, the cancer is selected from the group consisting of breast cancer, ovarian cancer (e.g., recurrent ovarian cancer), pancreatic cancer, testicular cancer (e.g., cisplatin-resistant germ cell cancer), prostate cancer (e.g., bone metastatic prostate cancer, prostate neoplasm, hormone resistant prostate cancer, castration resistant prostate cancer, advanced prostate cancer), dedifferentiated liposarcoma, urothelial carcinoma of the bladder (e.g., transitional cell carcinoma of the urothelium (TCCU)), adrenocortical carcinoma, brain cancer (e.g., recurrent malignant glioma), AML (acute myeloid leukemia) and CLL (chronic lymphocytic leukemia). In some embodiments, the cancer is prostate cancer, pancreatic cancer, ovarian cancer or breast cancer. In some embodiments, the cancer is prostate cancer, e.g., hormone resistant prostate cancer, or e.g., metastatic castration resistant prostate cancer (mCRPC). In some embodiments, the cancer is breast cancer. In some embodiments, the cancer is pancreatic cancer. In some embodiments, the cancer is ovarian cancer. In some embodiments, the cancer is a tumor of the sweat glands, for example, digital papillary adenocarcinoma.

[0146] In some embodiments, dendrimers for use in therapy (e.g., cancer therapy) have a core: JPEG0007588065000036.jpg3251.

[0147] In some embodiments, dendrimers for use in therapy (e.g., cancer therapy) have building units that are each: JPEG0007588065000037.jpg2451; where the acyl group of each building unit provides a covalent attachment point for bonding to the core or a previous generation building unit; and each nitrogen atom provides a covalent attachment point for covalently bonding to a subsequent generation building unit, the first terminal group or the second terminal group.

[0148] In some embodiments, dendrimers for use in therapy (e.g., cancer therapy) have first terminal groups (T1) that are each: JPEG0007588065000038.jpg4959.

[0149] In some embodiments, dendrimers for use in therapy (e.g., cancer therapy) each have a second terminal group that is JPEG0007588065000039.jpg2056, where the PEG group is a methoxy-terminated PEG having an average molecular weight in the range of about 1750-2500 daltons.

[0150] In some embodiments, dendrimers for use in therapy (eg, cancer therapy) have between 26 and 32 first end groups and between 28 and 32 second end groups.

[0151] In some embodiments, the dendrimer used in therapy (e.g., cancer therapy) is JPEG0007588065000040.jpg6274 (wherein T1' represents the first terminal group JPEG0007588065000041.jpg4858 or T1' represents H, and T1' has less than 5 H; T2' represents the second end group JPEG0007588065000042.jpg1952, where the PEG group is a methoxy-terminated PEG having a molecular weight in the range of about 1750 to 2500 daltons, or T2' represents H and less than five of T2' are H.

[0152] Drugs are usually co-administered with other drugs in combination therapy, especially during chemotherapy. Thus, in some embodiments, dendrimers are administered in combination with one or more additional therapeutic / pharmaceutical active agents, such as one or more additional anti-cancer agents. The dendrimer and one or more additional therapeutic / pharmaceutical active agents can be administered simultaneously, subsequently, or separately. For example, they can be administered as part of the same composition or by administration of separate compositions. The one or more additional pharmaceutical active agents can be, for example, anti-cancer agents for the treatment of prostate cancer or breast cancer, or for the treatment of, for example, pancreatic cancer or ovarian cancer. Examples of additional pharmaceutical active agents include chemotherapeutic and cytotoxic agents, immuno-oncology agents (such as checkpoint inhibitors), and antibody therapy. Examples of further pharma- ceutically active agents include paclitaxel, docetaxel, abraxane, clarithromycin, vinflunine, bavituximab, tocotrienols, gemcitabine, capecitabine, carboplatin, oxaliplatin, niraparib, folinic acid, 5-fluorouracil, irinotecan, tamsulosin, ADT, G-CSF, LHRH antagonists, bicalutamide, enzultamide, clarithromycin, vinflunine, bavituximab, and bevacizumab.

[0153] The current label for Jevtana® (free cabazitaxel) states that it is administered as a 1-hour intravenous infusion in combination with oral prednisone 10 mg administered daily throughout Jevtana® treatment. Additionally, to reduce the risk and / or severity of hypersensitivity, premedication with the following intravenous drugs at least 30 minutes prior to each dose of Jevtana® is recommended: (i) an antihistamine (dexchlorpheniramine 5 mg, or diphenhydramine 25 mg, or an equivalent antihistamine), (ii) a corticosteroid (dexamethasone 8 mg, or an equivalent steroid), and (iii) an H2 antagonist (ranitidine 50 mg, or an equivalent H2 antagonist).

[0154] In some embodiments, the dendrimer or composition comprising the dendrimer is not administered in combination with a steroid or other medication used to deliver Jevtana®. In some embodiments, the dendrimer or composition comprising the dendrimer is not administered as part of a regimen requiring premedication. In some embodiments, the dendrimer or composition comprising the dendrimer is not administered in combination with a drug that reduces the risk and / or severity of hypersensitivity, is not administered as part of a regimen requiring premedication with a drug that reduces the risk and / or severity of hypersensitivity, is not administered as part of a regimen requiring ongoing treatment with a drug that reduces the risk and / or severity of hypersensitivity. In some embodiments, the dendrimer or composition comprising the dendrimer is not administered in combination with an antihistamine, a corticosteroid or an H2 antagonist, is not administered as part of a regimen requiring premedication with an antihistamine, a corticosteroid or an H2 antagonist, is not administered as part of a regimen requiring ongoing treatment with an antihistamine, a corticosteroid (e.g., prednisone, prednisolone), an immunosuppressant or an H2 antagonist.

[0155] It will be understood that a therapeutically effective amount refers to a dendrimer administered in an amount sufficient to alleviate or prevent to some extent one or more of the symptoms of the disorder or condition being treated.The therapeutically effective amount of a dendrimer can be, for example, based on the amount of dendrimer administered.Alternatively, it can be determined based on the amount of active agent (cabazitaxel) that the dendrimer can theoretically deliver, for example, based on the loading amount of cabazitaxel on the dendrimer.

[0156] In some embodiments, the amount of dendrimer administered is between 5 and 100 mg of active agent / m 2 , 10-100mg of activator / m 2 , 5-50mg of activator / m 2 , 5-40mg of activator / m 2 , 5-30mg of activator / m 2 , 5-25mg of activator / m 2 , 5-20mg of activator / m 2 , 10-50mg of activator / m 2 , 20-40mg of activator / m 2 , 15-35mg of activator / m 2 , 10-20mg / m 2 , 20-30mg / m 2 , 20-50mg / m 2 , 25-50mg / m 2 , 30-40mg / m 2 , 25-35mg of activator / m 2 , 50-100mg of activator / m 2 , 50-75mg of activator / m 2 , or 75-100 mg of active agent / m 2 Cabazitaxel is sufficient to deliver 20–25 mg / m 2 The use of 10 mg / kg of active agent in mice has been demonstrated to be effective in mice with dendrimer-specific 10 mg / kg of active agent, and the following comparative mouse study demonstrated that similar or slightly higher doses of active agent were effective in dendrimers. 2 (FDA Guidance 2005) (human mg / kg dose converted to mg / m 2To convert to , this number can be multiplied by 37; FDA Guidance 2005).

[0157] In some embodiments, the amount of dendrimer administered is between 20 and 25 mg / m 2 In some embodiments, the amount of cabazitaxel delivered to the patient is in the range of 0.5-3 times the amount of cabazitaxel delivered upon administration of 100 mg / m of free cabazitaxel. In some embodiments, the amount of dendrimer administered is in the range of 20-25 mg / m 2 In some embodiments, the amount of cabazitaxel delivered to the patient ranges from 1 to 2 times the amount of cabazitaxel delivered upon administration of 100 mg / m of free cabazitaxel. In some embodiments, the amount of dendrimer administered ranges from 20 to 25 mg / m 2 In some embodiments, the amount of cabazitaxel delivered to the patient ranges from 0.5 to less than 1 times the amount of cabazitaxel delivered upon administration of 100 mg / m of free cabazitaxel. In some embodiments, the amount of dendrimer administered is 20 to 25 mg / m 2 In some embodiments, the amount of cabazitaxel delivered to the patient is in the range of 0.5-1.5 times the amount of cabazitaxel delivered upon administration of 100 mg / m of free cabazitaxel. In some embodiments, the amount of dendrimer administered is in the range of 20-25 mg / m 2 In some embodiments, the amount of dendrimer administered delivers to the patient an amount of cabazitaxel that is in the range of 0.8-1.2 times the amount of cabazitaxel delivered by administration of 100 mg / m2 of free cabazitaxel. In some embodiments, the amount of dendrimer administered delivers an amount of cabazitaxel substantially equivalent to the amount delivered by administration of an approved dosage of free cabazitaxel (e.g., Jevtana®). For example, as discussed above, the recommended dosage level of cabazitaxel is 20-25 mg / m2. 2 In some embodiments, the amount of dendrimer administered is 20-25 mg / m 2 The amount of dendrimer administered can be determined, for example, by reference to the amount of cabazitaxel that the dendrimer is capable of delivering (i.e., cabazitaxel loading).

[0158] In some embodiments, a therapeutically effective amount of the dendrimer is administered to a subject in need thereof at a predetermined frequency. In some embodiments, the dendrimer is administered to a subject in need thereof according to a dosing regimen in which the dendrimer is administered once every 1-4 weeks. In some embodiments, the dendrimer is administered to a subject in need thereof according to a dosing regimen in which the dendrimer is administered once every 3-4 weeks.

[0159] In some embodiments, the dendrimer or pharmaceutical composition is administered as a rapid infusion or bolus. In some embodiments, the infusion time is over a period of less than 1 hour, less than 30 minutes, or less than 20 minutes, for example, it may be administered over a period of about 20 minutes, 15 minutes, or 10 minutes. In some embodiments, the administration is as a bolus, for example, it may be administered over a period suitable for a bolus injection, for example, up to about 5 minutes, for example, ranging from 5 seconds to 5 minutes.

[0160] Surprisingly, it has been found that the dendrimers of the present disclosure have increased efficacy compared to direct administration of the free drug.

[0161] An equivalent dose of free cabazitaxel is the amount of free cabazitaxel equivalent to the amount of cabazitaxel contained (loaded) in the dose of dendrimer administered.

[0162] As used herein, the term "free" refers to a drug, i.e., cabazitaxel, that is not previously conjugated to a dendrimer. For example, direct administration of free cabazitaxel refers to direct administration of a cabazitaxel molecule that is not administered as conjugated to a dendrimer. An example of such a treatment is Jevtana®. As used herein, the terms "unconjugated" and "released" refer to a drug, i.e., cabazitaxel, that has been dissociated or cleaved from a dendrimer. Dissociation or cleavage can occur in vivo after administration of a drug-dendrimer conjugate.

[0163] In some embodiments, administration of the dendrimer provides enhanced clinical efficacy compared to administration of an equivalent dose of free cabazitaxel.

[0164] In some embodiments, the course of dendrimer administered is 20 or 25 mg / m 2 provides enhanced clinical efficacy compared to three times weekly dosing of cabazitaxel.

[0165] In some embodiments, administering the dendrimer comprises: in at least 10%, at least 20%, at least 30%, at least 40%, or at least 50% of the patient population; Relieving or eliminating symptoms related to cancer; A reduction in the size of cancerous tissue, Increased progression-free survival, and / or Delaying or preventing metastasis results.

[0166] Oncology drugs usually have significant side effects due to off-target toxicity such as hematotoxicity, neurotoxicity, cardiotoxicity, hepatotoxicity, nephrotoxicity, ototoxicity and encephalotoxicity. For example, taxanes such as cabazitaxel can cause the following adverse effects: infections, neutropenia, anemia, febrile neutropenia, hypersensitivity, thrombocytopenia, bone marrow toxicity, bone marrow suppression, neuropathy, taste disorders, dyspnea, constipation, anorexia, nail disorders, fluid retention, asthenia, pain, nausea, diarrhea, vomiting, fatigue, non-specific neurocognitive disorders, dizziness, encephalopathy, mucositis, alopecia, skin reactions and myalgia.

[0167] In some embodiments, administration of the dendrimer results in reduced toxicity compared to administration of an equivalent dose of free cabazitaxel. Drug toxicity refers to the extent to which damage occurs to an organism and is measured by off-target effects. In oncology, one such measurement of toxicity in animal models is weight loss, which determines the maximum tolerated dose (MTD). In humans, toxicity is generally determined by specific adverse events (AEs), typically including dose-limiting toxicity. It will be understood that in oncology, the therapeutic window is usually narrow, and off-target toxicity is considered a normal side effect of killing tumor cells.

[0168] In some embodiments, administration of the dendrimer results in reduced toxicity compared to administration of an equivalent dose of free cabazitaxel when used in methods of treating cancer, e.g., treating cancer such as breast cancer, ovarian cancer, pancreatic cancer or prostate cancer, e.g., hormone refractory prostate cancer, metastatic castration-resistant prostate cancer (mCRPC).

[0169] In some embodiments, the administration of the dendrimer is at 20 or 25 mg / m 2 This results in reduced toxicity compared with cabazitaxel given three times weekly.

[0170] In some embodiments, administration of the dendrimer is at least 20 or 25 mg / m when used in methods of treating cancer, e.g., breast cancer, ovarian cancer, pancreatic cancer, or prostate cancer, e.g., hormone refractory prostate cancer, metastatic castration resistant prostate cancer (mCRPC), or other cancers. 2 This results in reduced toxicity compared with cabazitaxel given three times weekly.

[0171] In some embodiments, the course of dendrimer administered is 20 or 25 mg / m 2 This results in reduced toxicity compared with cabazitaxel given three times weekly.

[0172] In some embodiments, administration of a course of dendrimer results in reduced toxicity in at least 10%, at least 20%, at least 30%, at least 40%, or at least 50% of the patient population.

[0173] Toxicology studies performed with the dendrimers of the present disclosure indicate that the dendrimers are less likely to induce neutropenia and therefore less toxic in the clinic compared to administration of an equivalent dose of free cabazitaxel.

[0174] Thus, in some embodiments, administration of the dendrimer results in reduced myelotoxicity, e.g., in the form of reduced neutropenia, lymphopenia, anemia and / or thrombocytopenia, as compared to administration of an equivalent dose of free cabazitaxel, hi some embodiments, administration of the dendrimer results in reduced neutropenia as compared to administration of an equivalent dose of free cabazitaxel.

[0175] In some embodiments, the course of dendrimer administered is 20 or 25 mg / m 2 results in reduced neutropenia, lymphopenia, anemia, and / or thrombocytopenia compared with cabazitaxel given three times weekly.

[0176] In some embodiments, administration of the dendrimer, when used in a method of treating cancer, results in reduced bone marrow toxicity, e.g., in the form of reduced neutropenia, lymphopenia, anemia and / or thrombocytopenia, compared to administration of an equivalent dose of free cabazitaxel. In some embodiments, administration of the dendrimer, when used in a method of treating cancer, e.g., breast cancer, ovarian cancer, pancreatic cancer or prostate cancer, e.g., hormone refractory prostate cancer, metastatic castration resistant prostate cancer (mCRPC), etc., results in reduced neutropenia, compared to administration of an equivalent dose of free cabazitaxel. In some embodiments, administration of the dendrimer, when used in a method of treating cancer, e.g., breast cancer, ovarian cancer, pancreatic cancer or prostate cancer, e.g., hormone refractory prostate cancer, metastatic castration resistant prostate cancer (mCRPC), etc., results in reduced neutropenia, compared to administration of an equivalent dose of free cabazitaxel. 2 This resulted in reduced neutropenia compared with cabazitaxel given three times weekly.

[0177] In some embodiments, the dendrimers provide a reduction in toxicity as measured by the number of patients with a particular AE (e.g., infection (cystitis, upper respiratory tract, herpes zoster, candidiasis, sepsis, influenza, UTI), fever, neutropenia, anemia, febrile neutropenia, thrombocytopenia, leukopenia, bone marrow toxicity, bone marrow suppression, neuropathy, hypersensitivity, dysgeusia, gastrointestinal toxicity, dyspnea, cough, abdominal pain, constipation, anorexia, nail disorders, fluid retention, asthenia, pain, nausea, diarrhea, vomiting, fatigue, nonspecific neurocognitive impairment, headache, dizziness, back pain, arthralgia, encephalopathy, mucositis, alopecia, skin reactions, and myalgia) by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% compared to direct administration of an equivalent dose of the free pharma- ceutically active agent. In one example, administration of the dendrimer results in less than 95%, less than 90%, less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, or less than 10% toxicity compared to direct administration of an equivalent dose of free cabazitaxel.

[0178] The dendrimers of the present disclosure surprisingly achieve a sustained pharmacokinetic profile of the unconjugated or released drug. This sustained pharmacokinetic profile indicates that the drug is present in vivo at therapeutically effective levels for an extended period of time. It will be appreciated that a longer exposure to the drug is desirable, as it may extend the therapeutic effect of the drug and allow for less frequent administration. In some embodiments, administration of the dendrimer provides a therapeutically effective plasma concentration of cabazitaxel for a longer period of time compared to administration of an equivalent dose of free cabazitaxel.

[0179] In addition to having a sustained in vivo pharmacokinetic profile that provides relatively long therapeutic exposure levels, dendrimers also achieve relatively low Cmax levels upon in vivo administration.

[0180] In some embodiments, administration of dendrimers provides a lower maximum concentration (Cmax) of unconjugated / released drug compared to direct administration of an equivalent dose of free drug. The maximum concentration (Cmax) of a drug is the maximum (or peak) serum concentration that a drug achieves in a designated compartment or test area of ​​the body after the drug is administered and before a second administration. It is important to be able to administer pharmaceuticals at a level sufficient to achieve therapeutic concentration levels, but it is understood that if the maximum concentration level reached is high, there is an increased risk of encountering certain off-target effects, side effects and toxicity. This is particularly problematic for compounds with short half-lives, because in such cases, in order to provide therapeutically effective levels of active agent for an extended period of time, it is necessary to increase the dose and therefore the Cmax, resulting in an increased likelihood of side effects. It is therefore highly desirable to be able to deliver pharma-ceutically active agents in a form that provides therapeutically effective levels over a sustained period of time, while at the same time avoiding administration at a level that achieves a very high maximum concentration (Cmax) in vivo.

[0181] In some embodiments, the dendrimers have a lower maximum concentration (Cmax) of unconjugated / released cabazitaxel compared to direct administration of an equivalent dose of free cabazitaxel. In some embodiments, the dendrimers have a lower maximum concentration (Cmax) of released / unconjugated cabazitaxel compared to direct administration of an equivalent dose of free cabazitaxel when used in a treatment method, e.g., for the treatment of cancer, such as breast cancer, ovarian cancer, pancreatic cancer or prostate cancer, e.g., hormone-resistant prostate cancer, metastatic castration-resistant prostate cancer (mCRPC).

[0182] In some embodiments, the dendrimer is at 20 or 25 mg / m 2 In some embodiments, the dendrimer has a lower maximum concentration (Cmax) of unconjugated / released cabazitaxel compared to direct administration of cabazitaxel at a dose of 20 or 25 mg / m. In some embodiments, the dendrimer is used in a treatment method, e.g., for the treatment of cancer, such as breast cancer, ovarian cancer, pancreatic cancer or prostate cancer, e.g., hormone refractory prostate cancer, metastatic castration resistant prostate cancer (mCRPC), and the like. 2 has a lower maximum concentration (Cmax) of released / unconjugated cabazitaxel compared to direct administration of cabazitaxel at a dose of

[0183] In some embodiments, administration of the dendrimer results in a maximum concentration (Cmax) of drug (i.e., released / unconjugated cabazitaxel) that is less than 90%, less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, or less than 5% of the Cmax obtained from direct administration of an equivalent dose of free cabazitaxel.

[0184] In some embodiments, a sufficient amount of dendrimer is administered to provide a maximum concentration (Cmax) of unconjugated cabazitaxel of less than 800 ng / mL, less than 500 ng / mL, less than 200 ng / mL, less than 100 ng / mL, less than 50 ng / mL, less than 25 ng / mL, or less than 20 ng / mL. In some embodiments, a sufficient amount of dendrimer is administered to provide a maximum concentration (Cmax) of unconjugated / released cabazitaxel of about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 55, about 60, about 65, about 70, about 75, about 80, about 85, about 80, about 95, or about 100 ng / mL.

[0185] AUC is the area under the curve of the plot of drug concentration in plasma against time. AUC represents the total drug exposure over time. It will be understood that AUC is usually proportional to the total amount of drug delivered to the body.

[0186] It will be appreciated that following administration of the dendrimer, and as some of the cabazitaxel is released from the dendrimer, there will be both unbound cabazitaxel in the body and cabazitaxel still bound to the dendrimer.

[0187] In some embodiments, administration of the dendrimer provides a greater AUC of total cabazitaxel (ie, both dendrimer-bound cabazitaxel and released cabazitaxel) compared to direct administration of an equivalent dose of free cabazitaxel.

[0188] In some embodiments, administration of the dendrimer provides a greater AUC of total cabazitaxel (i.e., both dendrimer-bound and released cabazitaxel) compared to direct administration of an equivalent dose of free cabazitaxel when used in a treatment method, e.g., for the treatment of cancers such as breast cancer, ovarian cancer, pancreatic cancer, or prostate cancer, e.g., hormone-refractory prostate cancer, metastatic castration-resistant prostate cancer (mCRPC). In some embodiments, administration of the dendrimer provides at least 1.5-fold, at least 2-fold, at least 3-fold, at least 4-fold, or at least 5-fold greater AUC of total cabazitaxel (i.e., both dendrimer-bound and released cabazitaxel) compared to direct administration of an equivalent dose of free cabazitaxel.

[0189] In some embodiments, administration of the dendrimer is used in a treatment method, e.g., in the treatment of cancer, such as breast cancer, ovarian cancer, pancreatic cancer or prostate cancer, e.g., hormone refractory prostate cancer, metastatic castration resistant prostate cancer (mCRPC), at a dose of 20 or 25 mg / m 2 In some embodiments, administration of the dendrimer provides a greater AUC of total cabazitaxel (i.e., both dendrimer-bound and released cabazitaxel) compared to direct administration of cabazitaxel at a dose of 20 or 25 mg / m 2 the AUC of total cabazitaxel (i.e., both dendrimer-bound cabazitaxel and released cabazitaxel) at least 1.5-fold, at least 2-fold, at least 3-fold, at least 4-fold, or at least 5-fold higher compared to direct administration of a dose of cabazitaxel.

[0190] In some embodiments, an amount of dendrimer is administered that provides an AUC of total cabazitaxel (i.e., both dendrimer-bound and released cabazitaxel) of at least 100,000, at least 110,000, at least 120,000, at least 130,000, at least 140,000, at least 150,000, at least 160,000, at least 170,000, at least 180,000, at least 190,000, or at least 200,000 ng.hr / mL. In some embodiments, an amount of dendrimer is administered that provides an AUC of total cabazitaxel (i.e., both dendrimer-bound and released cabazitaxel) of about 150,000, about 160,000, about 170,000, about 180,000, about 190,000, about 200,000, about 210,000, about 220,000 or about 230,000 ng.hr / mL.

[0191] In some embodiments, administration of the dendrimer provides an equivalent or greater AUC of unconjugated / released cabazitaxel compared to direct administration of an equivalent dose of free cabazitaxel.

[0192] In some embodiments, administration of the dendrimer provides an AUC of unconjugated / released cabazitaxel that is at least 1.1-fold, at least 1.2-fold, at least 1.3-fold, at least 1.4-fold, at least 1.5-fold, at least 1.6-fold, at least 1.7-fold, at least 1.8-fold, at least 1.9-fold, at least 2-fold, at least 2.5-fold, at least 3-fold, at least 3.5-fold, or at least 4-fold greater than the AUC of unconjugated / released cabazitaxel compared to direct administration of an equivalent dose of free cabazitaxel.

[0193] In some embodiments, administration of the dendrimer provides an AUC of unconjugated / released cabazitaxel that is 0.8-1.2-fold higher compared to direct administration of an equivalent dose of free cabazitaxel.

[0194] In some embodiments, administration of the dendrimer provides an equivalent or greater AUC of unconjugated / released cabazitaxel compared to direct administration of an equivalent dose of free cabazitaxel when used in a treatment method, e.g., for the treatment of cancers such as breast cancer, ovarian cancer, pancreatic cancer or prostate cancer, e.g., hormone refractory prostate cancer, metastatic castration-resistant prostate cancer (mCRPC).

[0195] In some embodiments, the administration of the dendrimer is at 20 or 25 mg / m 2 The present invention provides an equivalent or greater AUC of unconjugated / released cabazitaxel compared to direct administration of a dose of cabazitaxel.

[0196] In some embodiments, the administration of the dendrimer is at 20 or 25 mg / m 2 The present invention provides an AUC of unconjugated / released cabazitaxel that is at least 1.1-fold, at least 1.2-fold, at least 1.3-fold, at least 1.4-fold, at least 1.5-fold, at least 1.6-fold, at least 1.7-fold, at least 1.8-fold, at least 1.9-fold, at least 2-fold, at least 2.5-fold, at least 3-fold, at least 3.5-fold, or at least 4-fold greater than that of directly administered cabazitaxel at a dose of

[0197] In some embodiments, the administration of the dendrimer is at 20 or 25 mg / m 2 provides an AUC of unconjugated / released cabazitaxel of 0.8-fold to 1.2-fold compared to direct administration of cabazitaxel at a dose of 100 mg / kg.

[0198] In some embodiments, administration of the dendrimer is used in a treatment method, e.g., in the treatment of cancer, such as breast cancer, ovarian cancer, pancreatic cancer or prostate cancer, e.g., hormone refractory prostate cancer, metastatic castration resistant prostate cancer (mCRPC), at a dose of 20 or 25 mg / m 2 The present invention provides an equivalent or greater AUC of unconjugated / released cabazitaxel compared to direct administration of a dose of cabazitaxel.

[0199] In some embodiments, an amount of dendrimer is administered that provides a release / AUC of unconjugated cabazitaxel of at least 500, at least 600, at least 700, at least 800, at least 900, at least 1000, at least 1100, at least 1200, at least 1300, at least 1400, at least 1500, at least 1750, at least 2000, at least 2500, at least 3000, at least 3500, or at least 4000 ng.hr / mL.

[0200] In some embodiments, an amount of dendrimer is administered that provides a release / AUC of about 500, about 600, about 700, about 800, about 900, about 1000, about 1100, about 1200, about 1300, about 1400, about 1500, about 1600, about 1700, about 1800, about 2000, about 2500, about 3000, about 3500, or about 4000 g.hr / mL of unconjugated cabazitaxel.

[0201] Free cabazitaxel is characterized by a triphasic elimination profile with an early half-life averaging 4 minutes, followed by an intermediate half-life of 2 hours, and a prolonged terminal half-life averaging 95 hours. In some embodiments, administration of the dendrimer extends the terminal half-life (t) of unconjugated / released cabazitaxel by at least 12 hours, at least 24 hours, at least 30 hours, at least 40 hours, at least 48 hours, at least 50 hours, or at least 75 hours. 1 / 2 ) is provided.

[0202] It will be appreciated that any one or more of the above pharmacokinetic properties may provide better clinical efficacy compared to direct administration of free drug. In some embodiments, administration of the dendrimer provides better drug efficacy compared to direct administration of an equivalent dose of free drug. In some embodiments, the dendrimer provides an improved efficacy property selected from the group consisting of progression-free survival, time to progression, response rate (PR+CR), overall response rate, overall survival and duration of response compared to direct administration of an equivalent dose of free cabazitaxel. Dendrimer synthesis

[0203] The dendrimers of the present disclosure may be prepared by any suitable method, for example by reacting a cabazitaxel-containing precursor with a dendrimer intermediate already containing a PEG group to introduce a pharma- ceutically active agent, by reacting a PEG-containing precursor with a dendrimer intermediate already containing a cabazitaxel residue, or by reacting an intermediate containing a lysine group, a cabazitaxel residue and a PEG group with a dendrimer intermediate. Thus, in a fifth aspect, there is provided a method of making a dendrimer as defined herein, comprising: a) Cabazitaxel intermediates such as JPEG0007588065000043.jpg4858, wherein X is -OH or a leaving group, or X together with the attached C(O) group forms a carboxylate salt, i) a core unit (C); ii) a building unit, wherein each building unit (BU) is a lysine residue or an analogue thereof; Including, The core unit is covalently linked to two building units via amide bonds, each amide bond being formed between a nitrogen atom present in the core unit and a carbon atom of an acyl group present in a building unit; The dendrimer is a 5 generation building unit dendrimer; The building units of different generations are covalently linked to each other via amide bonds formed between a nitrogen atom present in one building unit and a carbon atom of an acyl group present in another building unit; The dendrimer comprises multiple second end groups (T2) each of which comprises a PEG group. and at least one-third of the nitrogen atoms present in the outer building units are each covalently bonded to a second end group; At least one-third of the nitrogen atoms present in the outer building units are unsubstituted and available for reaction with the first intermediate; a dendrimer intermediate, or a salt thereof; reacting under amide coupling conditions; or b) a PEG intermediate which is: JPEG0007588065000044.jpg1754, where PEG is a PEG-containing group; X is -OH or a leaving group, or X together with the attached C(O) group forms a carboxylate salt; i) a core unit (C); ii) a building unit, wherein each building unit (BU) is a lysine residue or an analogue thereof; Including, The core unit is covalently linked to two building units via amide bonds, each amide bond being formed between a nitrogen atom present in the core unit and a carbon atom of an acyl group present in a building unit; The dendrimer is a 5 generation building unit dendrimer; The building units of different generations are covalently linked to each other via amide bonds formed between a nitrogen atom present in one building unit and a carbon atom of an acyl group present in another building unit; The dendrimer comprises a plurality of first end groups (T1) each of which comprises a cabazitaxel residue covalently attached to a diglycolyl linker group. 1. A dendrimer intermediate further comprising: at least one-third of the nitrogen atoms present in the outer building units are each covalently bonded to a first end group; At least one-third of the nitrogen atoms present in the outer building units are unsubstituted; a dendrimer intermediate, or a salt thereof; reacting under amide coupling conditions; or c) a surface unit intermediate that is JPEG0007588065000045.jpg4577, where PEG is a PEG-containing group; X is -OH or a leaving group, or X together with the attached C(O) group forms a carboxylate salt; i) a core unit (C); ii) a building unit, wherein each building unit (BU) is a lysine residue or an analogue thereof; Including, The core unit is covalently linked to two building units via amide bonds, each amide bond being formed between a nitrogen atom present in the core unit and a carbon atom of an acyl group present in a building unit; It is a fourth generation building unit dendrimer intermediate; The building units of different generations are covalently linked to each other via amide bonds formed between a nitrogen atom present in one building unit and a carbon atom of an acyl group present in another building unit; The nitrogen atoms present in the outer building units of the dendrimer intermediate are unsubstituted; a dendrimer intermediate, or a salt thereof; reacting under amide coupling conditions A method is provided that includes:

[0204] Method variants a), b) and c) involve the formation of an amide bond by reaction of the -C(O)X group with an amine group present on the dendrimer intermediate. Any suitable amide forming conditions can be used. Typical examples of conditions include the use of a suitable solvent (e.g. dimethylformamide), optionally a suitable base, and a suitable temperature (e.g. ambient temperature, e.g. in the range of 15-30°C). When X is a leaving group, any suitable leaving group can be used, e.g. an activated ester. When X is an -OH group or when X, together with the C(O) group to which it is attached, forms a carboxylate salt, this group is typically converted to a suitable leaving group prior to reaction with the dendrimer intermediate, e.g. by use of a suitable amide coupling reagent, e.g. PyBOP.

[0205] Any suitable isolation and / or purification technique may be utilized, for example the dendrimers may be obtained by dissolution in a suitable solvent (eg THF) and precipitation by addition to a poor solvent (eg MTBE).

[0206] The cabazitaxel intermediate used in variant a) may itself be obtained, for example, by reacting cabazitaxel with diglycolic anhydride in the presence of a suitable solvent, such as dichloromethane, and a suitable base, such as triethylamine.

[0207] The surface unit intermediates used in variant c) may themselves be, for example i) PEG intermediates such as: JPEG0007588065000046.jpg1746, where PEG group is a PEG-containing group; X is -OH or a leaving group, or X together with the C(O) group to which it is attached forms a carboxylate salt, JPEG0007588065000047.jpg3744 (wherein PG1 is an amine protecting group (such as a Boc or Cbz group) and PG2 is an acid protecting group (such as a methyl or benzyl ester)) reacting with; ii) deprotecting PG1; iii) converting the product of step ii) into the following cabazitaxel intermediate: JPEG0007588065000048.jpg4555, where X is -OH or a leaving group, or X together with the C(O) group to which it is attached forms a carboxylate salt. reacting with; and iv) Deprotecting PG2 can be obtained by

[0208] The dendrimer intermediate used in variant a) may itself be, for example i) reacting a core unit (C) containing an amino group with a building unit which is a protected lysine or analogue thereof containing a -C(O)X group, where X is -OH or a leaving group, or -CO(X) forms a carboxylate, and the amino group present in the lysine or analogue is protected, to form an amide bond between the core unit and the building unit; ii) deprotecting any protecting groups present on the building units; iii) reacting a free amino group present in the building unit with a further building unit which is a protected lysine or analogue thereof, comprising a -C(O)X group, where X is -OH or a leaving group, or -CO(X) forms a carboxylate, and the amino group present in the lysine or analogue is protected, to form an amide bond between building units of different generations; iv) deprotecting any protecting groups present on the building units; v) repeating step iii) and step iv) until a fourth generation building unit is obtained; vi) Free amino groups present in the building units are JPEG0007588065000049.jpg3961 (wherein PG is a protecting group and X is -OH or a leaving group, or X together with the attached C(O) group forms a carboxylate salt) to form an amide bond therebetween; and vii) Deprotecting the protecting group PG The method can be obtained by a sequential process including:

[0209] Alternatively, the dendrimer intermediate used in variant a) may be, for example, a dendrimer intermediate prepared according to steps i) to v) above, and vi) reacting a free amino group present in a building unit with a further building unit which is a protected lysine or analogue thereof containing a -C(O)X group, where X is -OH or a leaving group, or -CO(X) forms a carboxylate, and the amino group present in the lysine or analogue is orthogonally protected, to form an amide bond between building units of different generations; vii) deprotecting the first set of amino protecting groups; viii) The free amino groups present in the building units are JPEG0007588065000050.jpg1750, where PEG group is a PEG-containing group, X is -OH or a leaving group, or X together with the attached C(O) group forms a carboxylate salt. reacting with; vii) deprotecting the second set of amino protecting groups. It can be obtained by performing the following.

[0210] The dendrimer intermediate used in variant b) can itself be prepared, for example, by carrying out steps i) to v) described above with respect to variant a), and vi) Free amino groups present in the building units are JPEG0007588065000051.jpg4158 (wherein PG is a protecting group and X is -OH or a leaving group, or X together with the attached C(O) group forms a carboxylate salt) to form an amide bond therebetween; and vii) Deprotecting the protecting group PG It can be obtained by performing the following.

[0211] Alternatively, the dendrimer intermediate used in variant b) can be, for example, a dendrimer intermediate prepared according to steps i) to v) above, and vi) reacting a free amino group present in a building unit with a further building unit which is a protected lysine or analogue thereof containing a -C(O)X group, where X is -OH or a leaving group, or -CO(X) forms a carboxylate, and the amino group present in the lysine or analogue is orthogonally protected, to form an amide bond between building units of different generations; vii) deprotecting the first set of amino protecting groups; viii) The free amino groups present in the building units are JPEG0007588065000052.jpg4150, where X is -OH or a leaving group, or X together with the C(O) group to which it is attached forms a carboxylate salt. reacting with; vii) deprotecting the second set of amino protecting groups. It can be obtained by performing the following.

[0212] The dendrimer intermediate used in variant c) can itself be obtained, for example, by carrying out steps i) to v) described above for variant a).

[0213] The present disclosure also provides synthetic intermediates useful for preparing dendrimers. Thus, the following dendrimers are JPEG0007588065000053.jpg3647 (wherein X is -OH or a leaving group, or X together with the attached C(O) group forms a carboxylate salt). Also provided are intermediates for preparing the compound: Such intermediates can be prepared, for example, as described above.

[0214] The following dendrimers JPEG0007588065000054.jpg3765, where PEG is a PEG-containing group; X is -OH or a leaving group, or X together with the C(O) group to which it is attached forms a carboxylate salt. Also provided are intermediates for preparing the compound: Such intermediates can be prepared, for example, as described above.

[0215] The present disclosure will now be described with reference to the following examples illustrating some particular aspects of the present disclosure, however it will be understood that the specificity of the following description of the present disclosure does not supersede the generality of the preceding description of the present disclosure. Working Example Example 1: BHALys[Lys] 32 [α-NH 2 TFA] 32 [ε-PEG about 2100]32 ‡ Synthesis and characterization of

[0216] The dendrimers depicted in the following examples include reference to the core and building units of the outermost generation of the dendrimer. Subsurface generations are not shown. Dendrimer BHALys[Lys] 32 is the expression BHALys[Lys]2[Lys]4[Lys]8[Lys] 16 [Lys] 32 This represents a fifth generation dendrimer having the following structure:

[0217] 32‡ is PEG 約2100 relates to the theoretical number of ε surface amino groups on the dendrimer available for substitution with BHALys[Lys] 32PEG conjugated to 約2100 The actual average number of groups is 1 Experimentally determined by H NMR (BHALys[Lys] 32 [α-NH2-TFA] 32 [ε-PEG 約2100 ] 32‡ (see the section below in this Example entitled Characterization of BHALys[Boc]2

[0218] Solid α,ε-(t-Boc)2-(L)-lysine p-nitrophenol ester (2.787 kg, 5.96 mol) was added over 15 minutes to a solution of aminodiphenylmethane (benzhydrylamine) (0.99 kg, 5.4 mol) in anhydrous acetonitrile (4.0 L), DMF (1.0 L) and triethylamine (1.09 kg). The reaction mixture was stirred at 20° C. overnight. The reaction mixture was then warmed to 35° C. and aqueous sodium hydroxide (0.5 N, 10 L) was added slowly over 30 minutes. The mixture was stirred for an additional 30 minutes and then filtered. The solid cake was washed with water and dried to constant weight (2.76 kg, 5.4 mol) in 100% yield. 1 H NMR (CD3OD) δ 7.3 (m, 10H, Ph calc. 10H); 6.2 (s, 1H, CH-Ph calc. 1H); 4.08 (m, α-CH, 1H), 3.18 (br, ε-CH2) and 2.99 (m, ε-CH2 2H); 1.7-1.2 (br, β, γ, δ-CH2) and 1.43 (s, tBu) total 25H calc. 24H for β, γ, δ-CH2 and tBu. MS (ESI+ve) found 534.2 [M+Na] + C 29 H 41 N3O5Na [M+Na] + The calculated value for is 534.7. BHALys[HCl]2

[0219] A solution of concentrated HCl (1.5 L) in methanol (1.5 L) was slowly added in three portions to a stirred suspension of BHALys[Boc]2 (780.5 g, 1.52 mol) in methanol (1.5 L) at a rate that minimized excessive foaming. The reaction mixture was stirred for an additional 30 min and then concentrated under vacuum at 35° C. The residue was dissolved in water (3.4 L) and concentrated under vacuum at 35° C. twice, then stored under vacuum overnight. Acetonitrile (3.4 L) was then added and the residue was again concentrated under vacuum at 35° C. to give BHALys[HCl]2 as a white solid (586 g, 1.52 mol) in 100% yield. 1 H NMR(D2O)δ7.23(br m,10H,Ph calculation 10H);5.99(s,1H,CH-Ph2 calculation 1H);3.92(t,J=6.5 Hz,α-CH,1H,calculation 1H);2.71(t,J=7.8 Hz,ε-CH2,2H, calculation 2H); 1.78(m,β,γ,δ-CH2,2H), 1.47(m,β,γ,δ-CH2,2H) and 1.17(m,β,γ,δ-CH2,2H, total 6H calculation 6H). MS(ESI+ve) Actual value 312 [M+H] + C 19 H 26 NO [M+H] + Calculated value for 312. BHALys[Lys]2[Boc]4

[0220] To a suspension of BHALys[HCl]2 (586 g, 1.52 mmol) in anhydrous DMF (3.8 L) was added triethylamine (1.08 kg) slowly to maintain the reaction temperature below 30° C. Solid α,ε-(t-Boc)2-(L)-lysine p-nitrophenol ester (1.49 kg) was added slowly in three portions with 2 h stirring between additions. The reaction was allowed to stir overnight. Aqueous sodium hydroxide (0.5 M, 17 L) was added slowly to the well-stirred mixture and stirring was maintained until the solid precipitate was free to move. The precipitate was collected by filtration and the solid cake was washed well with water (2×4 L) and then acetone / water (1:4, 2×4 L). The solid was slurried again with water, then filtered and dried under vacuum overnight to give BHALys[Lys]2[Boc]4 (1.51 kg) in 100% yield. 1 H NMR (CD3OD) δ 7.3 (m, 10H, Ph calc. 10H); 6.2 (s, 1H, CH-Ph2 calc. 1H); 4.21 (m, α-CH), 4.02 (m, α-CH) and 3.93 (m, α-CH, total 3H, calc. 3H); 3.15 (m, ε-CH2) and 3.00 (m, ε-CH2 total 6H, calc. 6H); 1.7-1.3 (br, β, γ, δ-CH2) and 1.43 (s, tBu) total 57H for β, γ, δ-CH2 and tBu, calc. 54H. MS (ESI+ve) found 868.6 [M-Boc] + ;990.7 [M+Na] + C 51 H 81 N7O 11 Na [M+Na] + The calculated value for is 991.1. BHALys[Lys]2[HCl]4

[0221] BHALys[Lys]2[Boc]4 (1.41 kg, 1.46 mol) was suspended in methanol (1.7 L) with stirring at 35°C. Hydrochloric acid (1.7 L) was mixed with methanol (1.7 L) and the resulting solution was added in four portions to the dendrimer suspension and left stirring for 30 min. The solvent was removed under reduced pressure and worked up with two successive strips of water (3.5 L) followed by two successive strips of acetonitrile (4 L) to give BHALys[Lys]2[HCl]4 (1.05 Kg, 1.46 mmol) in 102% yield. 1 H NMR(D2O)δ 7.4(br m,10H,Ph calculation 10H);6.14(s,1H,CH-Ph2 calculation 1H);4.47(t,J=7.5 Hz,α-CH,1H),4.04(t,J=6.5 Hz,α-CH,1H),3.91(t,J=6.8 Hz,α-CH,1H, total 3H, calculation 3H); 3.21(t,J=7.4 Hz,ε-CH2,2H), 3.01(t,J=7.8 Hz,ε-CH2,2H) and 2.74(t,J=7.8 Hz,ε-CH2,2H, total 6H, calculation 6H);1.88(m,β,γ,δ-CH2),1.71(m,β,γ,δ-CH2),1.57(m,β,γ,δ-CH2) and 1.35(m,β,γ,δ-CH2 total 19H, calculation 18H. BHALys[Lys]4[Boc]8

[0222] BHALys[Lys]2[HCl]4 (1.05 Kg, 1.47 mol) was dissolved in DMF (5.6 L) and triethylamine (2.19 L). α,ε-(t-Boc)2-(L)-Lysine p-nitrophenol ester (2.35 kg, 5.03 mol) was added in three portions and the reaction was stirred at 25° C. overnight. NaOH (0.5 M, 22 L) solution was added and the resulting mixture was filtered, washed with water (42 L) and then air-dried. The solid was dried under vacuum at 45° C. to give BHALys[Lys]4[Boc]8 (2.09 kg, 1.11 mol) in 76% yield. 1H NMR (CD3OD) δ 7.3 (m, 10H, Ph calculated 10H); 6.2 (s, 1H, CH-Ph2 calculated 1H); 4.43 (m, α-CH), 4.34 (m, α-CH), 4.25 (m, α-CH) and 3.98 (br, α-CH, total 7H, calculated 7H); 3.15 (br, ε-CH2) and 3.02 (br, ε-CH2 total 14H, calculated 14H); 1.9-1.2 (br, β, γ, δ-CH2) and 1.44 (br s, tBu) total 122H for β, γ, δ-CH2 and tBu, calculated 144H. BHALys[Lys]4[TFA]8

[0223] To a stirred suspension of BHALys[Lys]4[Boc]8 (4 g, 2.13 mmol) in DCM (18 mL) at 0° C. was added TFA (13 mL). The solids dissolved and the solution was stirred overnight under an argon atmosphere. The solvent was removed under vacuum and residual TFA was removed by trituration with diethyl ether (100 mL). The product was redissolved in water and then lyophilized to give BHALys[Lys]4[TFA]8 as an off-white solid (4.27 g, 2.14 mmol) in 101% yield. 1 H NMR(D2O)δ 7.21(br m,10H,Ph calculation 10H);5.91(s,1H,CH-Ph2 calculation 1H);4.17(t,J=7.4 Hz,α-CH,1H),4.09(t,J=7.1 Hz,α-CH,1H),4.02(t,J=7.2 Hz,α-CH,1H,3.84(t,J=6.5 Hz,α-CH,2H),3.73(t,J=6.7 Hz,α-CH,1H),3.67(t,J=6.7 Hz, α-CH, 1H, total 7H, calculation 7H); 3.0(m,ε-CH2), 2.93(m,ε-CH2) and 2.79(b,ε-CH2, total 15H, calculation 14H) );1.7(br,β,γ,δ-CH2),1.5(br,β,γ,δ-CH2),1.57(m,β,γ,δ-CH2) and 1.25(br,β,γ,δ-CH2 Total 45H, calculation 42H). MS(ESI+ve) Actual value 541.4 [M+2H] 2+ ;C 55 H 99 N 15 O7[M+2H] 2+The calculated value for is 541.2. BHALys[Lys]8[Boc] 16

[0224] A solution of α,ε-(t-Boc)2-(L)-lysine p-nitrophenol ester (1.89 g, 4.05 mmol) in DMF (25 mL) was added to a solution of BHALys[Lys]4[NH2TFA]8 (644 mg, 0.32 mmol) and triethylamine (0.72 mL, 5.2 mmol) in DMF (25 mL) and the reaction was left stirring overnight under argon atmosphere. The reaction mixture was poured into ice / water (500 mL) then filtered and the collected solid was dried under vacuum overnight. The dried solid was washed extensively with acetonitrile to give BHALys[Lys]8[Boc] 16 was obtained as an off-white solid (0.82 g, 0.22 mmol) in 68% yield. 1 H NMR (CD3OD) δ 7.3 (m, 10H, Ph calc. 10H); 6.2 (br s, 1H, CH-Ph2 calc. 1H); 4.48 (br,α-CH), 4.30 (br,α-CH) and 4.05 (br,α-CH, total 16H calc. 15H); 3.18 (br,ε-CH2) and 3.02 (m,ε-CH2 total 31H, calc. 30H); 1.9-1.4 (br,β,γ,δ-CH2) and 1.47 (br s,tBu) total 240H for β,γ,δ-CH2 and tBu, calc. 234H. MS (ESI+ve) found 3509 [M+H-(Boc)2] + C 173 H 306 N 31 O 43 [M+H-(Boc)2] + Calculated for 3508.5; 3408 [M+H-(Boc)3] + C 168 H 298 N 31 O 41 [M+H-(Boc)3] + The calculated value for is 3408.4. BHALys[Lys]8[TFA] 16

[0225] A solution of TFA / DCM (1:1, 19 mL) was added to BHALys[Lys]8[Boc] 16 (800 mg, 0.22 mmol) was slowly added to a stirred suspension of BHALys[Lys]8[TFA] in DCM (25 mL). The solids dissolved and the solution was stirred overnight under an argon atmosphere. The solvent was removed under vacuum and residual TFA was removed by repeated lyophilization of the residue to give BHALys[Lys]8[TFA] 16 was obtained as an off-white lyophilizate (848 mg, 0.22 mmol) in 100% yield. 1 H NMR(D2O)δ 7.3(br m,10H,Ph calculation 10H); 6.08 (s, 1H, CH-Ph2 calculation 1H); 4.3 (m, α-CH), 4.18 (m, α-CH), 4.0 (m, α-CH) and 3.89 (m, α-CH, total 16H, calculation 15H); 3.18 (br ,ε-CH2) and 2.94 (m,ε-CH2 total 32H, calculated 30H); 1.9(m,β,γ,δ-CH2), 1.68(m,β,γ,δ-CH2) and 1.4(m,β,γ,δ-CH2 total 99H, calculated 90H). MS(ESI+ve) Actual value 2106 [M+H] + C 103 H 194 N 31 O 15 [M+H] + The calculated value for is 2106.9. BHALys[Lys] 16 [Boc] 32

[0226] A solution of α,ε-(t-Boc)2-(L)-lysine p-nitrophenol ester (1.89 g, 4.05 mmol) in DMF (25 mL) was added to BHALys[Lys]8[TFA] 16 To a solution of BHALys[Lys] (644 mg, 0.32 mmol) and triethylamine (0.72 mL, 5.2 mmol) in DMF (25 mL) was added and the reaction was left stirring overnight under an argon atmosphere. The reaction was poured into ice / water (500 mL) then filtered and the collected solid was dried under vacuum overnight. The dried solid was washed extensively with acetonitrile to give BHALys[Lys] 16 [Boc] 32was obtained as an off-white solid (0.82 g, 0.22 mmol) in 68% yield. 1 H NMR (CD3OD) δ 7.28 (m, 9H, Ph calc. 10H); 6.2 (br s, 1H, CH-Ph2 calc. 1H); 4.53 (br,α-CH), 4.32 (br,α-CH) and 4.05 (br,α-CH, total 35H, calc. 31H); 3.18 (br,ε-CH2) and 3.04 (m,ε-CH2 total 67H, calc. 62H); 1.9-1.5 (br,β,γ,δ-CH2) and 1.47 (br s,tBu) total 474H calc. for β,γ,δ-CH2 and tBu, 474H. MS (ESI+ve) found 6963 [M+H-(Boc)4] + C 339 H 610 N 63 O 87 [M+H-(Boc)4] + Calculated for 6960.9; 6862 [M+H-(Boc)5] + C 334 H 604 N 63 O 85 [M+H-(Boc)5] + The calculated value for is 6860.8. BHALys[Lys] 16 [TFA] 32

[0227] A solution of TFA / DCM (1:1, 19 mL) was added to BHALys[Lys] 16 [Boc] 32 (800 mg, 0.11 mmol) was slowly added to a stirred suspension of BHALys[Lys] in DCM (25 mL). The solids dissolved and the solution was stirred overnight under an argon atmosphere. The solvent was removed under vacuum and residual TFA was removed by repeated lyophilization of the residue to give BHALys[Lys] 16 [TFA] 32 was obtained as an off-white lyophilizate (847 mg, 0.11 mmol) in 100% yield. 1H NMR(D2O)δ 7.3(br m,11H,Ph calculation 10H); 6.06 (s, 1H, CH-Ph2 calculation 1H); 4.3 (m, α-CH), 4.19 (m, α-CH), 4.0 (m, α-CH) and 3.88 (m, α-CH, total 35H, calculation 31H); 3.15 (br, ε-CH2) and 2.98 (m,ε-CH2 total 69H, calculated 62H); 1.88(m,β,γ,δ-CH2), 1.7(m,β,γ,δ-CH2) and 1.42(m,β,γ,δ-CH2 total 215H, calculated 186H). MS(ESI+ve) Actual value 4158 [M+H] + C 199 H 386 N 63 O 31 [M+H] + Calculated value for 4157.6 HO-Lys(α-BOC)(ε-PEG 約2100 )

[0228] DIPEA (0.37 mL, 2.10 mmol) was dissolved in NHS-PEG in DMF (20 mL). 約2100 (2.29g, 1.05mmol) (wherein, PEG 約2100 To an ice-cold mixture of HO-Lys(BOC)(PEG) and N-α-t-BOC-L-lysine (0.26 g, 1.05 mmol) was added HO-Lys(BOC)(PEG). The stirred mixture was allowed to warm to room temperature overnight and then the solvent was removed in vacuo after filtering off the remaining solids (0.45 μm PALL acrodisc). The residue was dissolved in ACN / HO (1:3, 54 mL) and purified by PREP HPLC (Waters XBridge C18, 5 μm, 19 × 150 mm, 25–32% ACN (5–15 min), 32–60% ACN (15–20 min), no buffer, 8 mL / min, RT = 17 min) to give HO-Lys(BOC)(PEG). 2100 ) 1.41 g (56%) was obtained. 1H NMR(CD3OD)δ 3.96-4.09(m,1H),3.34-3.87(m,188H);3.32(s,3H),3.15(q,J=6.0 Hz,2H),2.40(t,J=6.2 Hz, 2H), 1.28-1.88 (m, 6H), 1.41 (s, 9H). BHALys[Lys] 32 [α-BOC] 32 [ε-PEG 約2100 ] 32‡

[0229] BHALys[Lys] in DMF (20 mL) 16 [TFA] 32 To a stirred mixture of PyBOP (0.19 g, 24 μmol) and Lys(BOC)(PEG) (0.86 mL, 4.86 mmol) was added DIPEA (0.86 mL, 4.86 mmol). This mixture was then treated with PyBOP (0.62 g, 1.20 mmol) and Lys(BOC)(PEG) (0.86 mL, 4.86 mmol) in DMF (20 mL) at room temperature. 約2100 ) (2.94 g, 1.20 mmol). The reaction mixture was left stirring overnight and then diluted with water (200 mL). The aqueous mixture was subjected to centramate filtration (5k membrane, 20 L water). The retentate was lyophilized to give 1.27 g (73%) of the desired dendrimer. HPLC (C8 XBridge, 3 × 100 mm, gradient: 5% ACN (0-1 min), 5-80% ACN / H2O (1-7 min), 80% ACN (7-12 min), 80-5% ACN (12-13 min), 5% ACN (13-15 min), 214 nm, 0.1% TFA) Rf (min) = 8.52.1H NMR (300 MHz, DO) δ (ppm): 1.10-2.10 (m, Lys CH 2( β,χ,δ) and BOC,666H),3.02-3.36(m,Lys CH 2( ε),110H),3.40(s,PEG-OMe,98H),3.40-4.20(m,PEG-OCH2,5750H+Lys CH surface,32H),4.20-4.50(m,Lys,CH interior 32H),7.20-7.54(m,BHA,8H). 1 1 H NMR shows approximately 29 PEG. BHALys[Lys] 32 [α-NH2TFA]32 [ε-PEG 約2100 ] 32‡

[0230] BHALys[Lys] 32 [α-BOC] 32 [ε-PEG 約2100 ] 32 1.27 g (17.4 μmol) was stirred in TFA / DCM (1:1, 20 mL) at room temperature overnight. The volatiles were removed in vacuo and the residue was then dissolved in water (30 mL). The mixture was then concentrated. This process was repeated two more times, followed by lyophilization to give 1.35 g (106%) of the desired product as a viscous colorless oil. HPLC (C8 XBridge, 3×100 mm, gradient: 5% ACN (0-1 min), 5-80% ACN / H2O) (1-7 min), 80% ACN (7-12 min), 80-5% ACN (12-13 min), 5% ACN (13-15 min), 214 nm, 0.1% TFA) Rf (min) = 8.51. 1 H-nmr(300MHz,D2O)δ(ppm):1.22-2.08(Lys CH 2( (β,χ,δ),378H),3.00-3.26(Lys CH2(ε),129H),3.40(PEG-OMe,96H),3.45-4.18(PEG-OCH2,5610H+Lys CH surface, 32H), 4.20-4.46 (Lys, CH interior, 33H), 7.24-7.48 (8H, BHA). 1 1 H NMR shows approximately 29 PEG. BHALys[Lys] 32 [α-NH2TFA] 32 [ε-PEG 約2100 ] 32‡ Characterization

[0231] Table 1 shows the synthesized BHALys[Lys] 32 [α-NH2TFA] 32 [ε-PEG 約2100 ] 32# The actual number of PEG chains on the dendrimer is also shown in 1 Calculated by H NMR. Table 1. BHALys[Lys]32 [α-NH2TFA] 32 [ε-PEG 約2100 ] 32‡ Various batches of JPEG0007588065000055.jpg55147 * The number of PEGs is calculated from proton NMR. For batch 1: Number of PEGs = number of protons (integral) in the PEG region of the NMR (3.4-4.2 ppm) / average (mean) number of protons per PEG chain (CoA PEG / 44 Da x 4H). =5706H / (2200 / 44×4) =28.53 (approximately 29 PEG units) ** Molecular weights estimated by adding the MWs of the various components. For batch 1: Total MW = Mw of dendrimer + Mw of TFA + Mw of PEG =BHALys[Lys] 32 +32(TFA)+29(PEG) =8,258+3,648+63800 = approx. 75.7 kDa Table 2. BHALys[Lys] 32 [α-NH2TFA] 32 [ε-PEG 約2100 ] 32‡ About the different batches of 1 H NMR data JPEG0007588065000056.jpg110131 Example 2: Synthesis of linker-cabazitaxel [DGA-cabazitaxel] where the linker is diglycolic acid (DGA)

[0232] To a solution of cabazitaxel (2.00 g, 2.39 mmol) in dichloromethane (30 mL, 15 volumes) was added diglycolic anhydride (320.70 mg, 2.62 mmol, 1.1 equiv, 95% purity). After stirring for 5 min, triethylamine (500 μL, 3.59 mmol, 1.5 equiv) was added. The reaction mixture was stirred at room temperature for 1.5 h. LC-MS analysis (eluent: 40-80% acetonitrile in water with 0.1% 10 mM ammonium formate buffer) showed the presence of less than 1% starting material. The reaction mixture was diluted with 30 mL of DCM and then washed twice with pH=3 sodium chloride (5%) and sodium phosphate (1%) buffer (30 mL). During the first wash, the pH rose to 6.0, so 1 M aqueous HCl (2.0 mL) was added to readjust the pH to 3.0. The layers were separated. The DCM extract was dried over MgSO4 (3.2 g) and filtered through a glass sintered funnel. The funnel was washed with 5 mL of DCM twice (10 mL). The filtrate was evaporated to give a white solid. Yield = 2.03 g, 88.5%. 1H NMR:DMSO-d6.δ(ppm):0.97(s,3H),0.99(s,3H),1.38(s,9H),1.46-1.60(m,5H),1.7 7-1.85(m,4H),2.23(s,3H),2.62-2.75(m,1H),3.22(s,3H),3.29(s,3H),3.59(d,J=6 Hz,1H),3.76(dd,J=6Hz and 12 Hz,1H),4.02(s,2H),4.14(s,2H),4.31(d,J=18Hz,1H),4.40(d,J=15 Hz,1H),4.51(s,1H),4.71(s,1H),4.96(d,J=9 Hz,1H),5.06(t,J=9 Hz,1H),5.17(d,J=6 Hz,1H),5.38(d,J=9 Hz,1H),5.82(t,J=9 Hz,1H),7.19(t,J=9 Hz,1H),7.35-7.46(m,4H),7.64-7.77(m,3H),7.88(d,J=9 Hz,1H),7.98(d,J=6 Hz,2H). LC-MS: C8 XBridge 3.0×100mm, 120A, 3.5μm. 40-80% ACN / H2O (1-7 min), 80% ACN (7-9 min), 80-40% ACN (9-11 min), 40% ACN (11-15 min), 0.1% 10 mM ammonium formate Rf (min) = 5.76. ESI (+ve) measured value [M+OH] + =969. C 49 H 61 NO 18 Calculated for = 952.02 Da. In process analysis: A 25 μl aliquot was diluted with 1 ml acetonitrile. Material isolated: Approximately 1.0 mg / ml solution in acetonitrile. Example 3: BHALys[Lys] 32 [α-DGA-cabazitaxel] 32† [ε-PEG 約2100 ] 32‡ Synthesis of (SPL9048) JPEG0007588065000057.jpg6074

[0233] PEG is -C(O)CH2-PEG 約2100 (In the formula, PEG 約2100represents a methoxy-terminated PEG group having an average molecular weight of approximately 2100 daltons (e.g., an average molecular weight in the range of about 1900 to 2300); The ● represents a residue of cabazitaxel.

[0234] Note: 32† refers to the theoretical number of α-surface amino groups on the dendrimer available for substitution with DGA-cabazitaxel. 32 The actual average number of DGA-cabazitaxel groups bound to the 1 It was experimentally determined by 1 H NMR.

[0235] To a solution of DGA-cabazitaxel (2.020 g, 2.12 mmol, 1.2 equiv. / NH2) in DMF (20 mL, 4.8 vol.) was added solid PyBOP (1.15 g, 2.21 mmol, 1.25 equiv. / NH2). After stirring at rt for 5 min, solid BHALys[Lys] 32 [α-NH2TFA] 32 [ε-PEG 約2100 ] 32‡ (4.19 g, 55.25 μmol) was added. DMF (3 mL) was used to rinse residual solids from the vial. The suspension was stirred at RT and the mixture became homogenous within 15 min. NMM (0.97 mL, 8.84 mmol, 5 equiv. / NH2) was added. A pale yellow solution formed and was stirred at rt for 24 h. The solution was diluted with ACN (24 mL) and filtered through a 0.45 μm filter. BHALys[Lys] 32 [α-DGA-cabazitaxel] 32† [ε-PEG 約2100 ] 32‡ , 0.1m 2 The eluate was isolated by ultrafiltration (15 diafiltration volumes) in acetonitrile using a 10 kda Pelicon 3 regenerated cellulose membrane. The retentate was concentrated in vacuo to give a yellow gum, which was dissolved in THF (60 mL) and filtered through a 0.45 μm filter. The filtrate was concentrated in vacuo to give a gum. The yellow gum was dissolved in THF (27.5 ml, 5.6 g of BHALys[Lys] 32[α-DGA-cabazitaxel] 32† [ε-PEG 約2100 ] 32‡ The 2,3'-dimethylformamide was dissolved in 10 mL of MTBE (4.9 vol. based on theoretical yield of 100 mL) and added via addition funnel over 1 h to vigorously stirred MTBE (110 mL, 20 vol.) and cooled in an ice bath and under N2. A fine white suspension formed with some clumps and some material adhering to the flask walls. Once addition was complete, the suspension was stirred on ice for an additional 60 min. The flask was then removed from the ice bath and warmed to rt with stirring. Most of the solids on the flask walls were removed using a spatula and the solids were collected by filtration through a P3 sinter funnel. A metal spatula was used to break up the clumps and the filtered solids were washed with MTBE (2 x 28 mL). The wet cake was transferred to a vial and the residual MTBE was removed under vacuum at room temperature to give a fine white powder; 5.35 g, 94.9%. 1 H NMR: CD3OD-d4. δ(ppm): 1.13-2.73(m, 1225H), 3.23-3.30(m, 57H), 3.37(s, 99H), 3.39-3.97(m, 5720H), 4.04-4.50(m, 114H), 5.003(br s, 27H), 5.39-5.6.15(m, 108H), 7.28-8.10(m, 334H). 3,4,5-trichloropyridine was used as an internal standard and the loading was calculated by comparing the cabazitaxel aromatic signal with the 3,4,5-trichloropyridine signal. Theoretical molecular weight of the conjugate: 102 kDa. 1H NMR suggests 29.8 CTX / dendrimer. The actual molecular weight is approximately 100 kDa (24.9 wt% CTX). Over 10 batches produced, cabazitaxel loading ranged from 24.2% to 26%. HPLC (C8 Phenomenex Kinetex 2.1 x 75 mm, 100A, 2.6 μm. 5-45-90% ACN (with 0.1% TFA) in water (with 0.1% TFA) gradient: 5% (0-1 min), 5-45% ACN / H2O (1-2 min), 45% ACN (2-10 min), 45-90% (10-14 min), 90% (14-18 min), 90-5% ACN (18-18.1 min), 5% ACN (18.1-20 min). Rf (min) = 14.03. In process analysis: A 5 μL aliquot was diluted with 1 mL acetonitrile. Isolated material: approximately 3.0 mg / mL solution in acetonitrile. Example 4: Efficacy of dendrimer compounds in SCID mice

[0236] Example 4 compares the efficacy of dendrimer compounds in SCID mice.

[0237] In the following experiments and figures: SPL9005 is BHALys[Lys] 32 [α-TDA-cabazitaxel] 32† [ε-PEG 約2100 ] 32‡ and; SPL9048 is BHALys[Lys] 32 [α-DGA-cabazitaxel] 32† [ε-PEG 約2100 ] 32‡ It is.

[0238] SPL9005 differs from SPL9048 in that it contains a TDA (thiodiglycolyl) linking group instead of a diglycolyl linking group (i.e., -S- instead of -O- present in the diglycolyl linker). SPL9005 was prepared by a synthetic method similar to that used to prepare SPL9048.

[0239] References to administered amounts (mg / kg) for dendrimer compounds are references to the amount of cabazitaxel that can theoretically be released by the dendrimer. DU145 mouse xenograft prostate cancer model study

[0240] A DU145 mouse xenograft prostate cancer model study was conducted to evaluate the antitumor efficacy profile of SPL9048 versus comparator compounds, free cabazitaxel (Jevtana®) and SPL9005 (BHALys[Lys] 32 [α-TDA-cabazitaxel] 32† [ε-PEG 約2100 ] 32‡ ) was decided.

[0241] Dendrimer compounds were pre-weighed into glass vials, stored at 20°C until use, and dissolved in saline immediately prior to administration. Cabazitaxel was prepared fresh for each day of administration. An aliquot of the cabazitaxel concentrate was removed under sterile conditions and mixed with 13% ethanol diluent to create a 10 mg / ml working stock solution. Dosing solutions of 4.5 and 5.5 mg / mL were prepared from this working stock immediately prior to injection.

[0242] Male SCID mice (7–8 weeks old) were inoculated with 3 × 10 6 DU145 cells were inoculated subcutaneously into the flank. Mice were weighed and tumors were measured 2-3 times a week using electronic calipers. Tumor volumes (mm 3 ) is length (mm) / 2 × width (mm) 2 On day 24 after implantation (referred to as day 1), tumors of similar size (mean tumor volume 105 mm) were 3Mice bearing 10-mg / kg BALF were randomized into 5 groups of 10 animals. Treatment groups were saline, cabazitaxel (9 and 11 mg / kg), SPL-9048 (9 mg / kg) and SPL-9005 (25 mg / kg). Test compounds were administered intravenously by tail vein injection at 0.1 ml / 10 g body weight on days 1, 8 and 15. Cabazitaxel was administered at 0.05 ml / 10 g body weight. Mice were given a small dish containing nutritional supplements (mixed with food dust) daily. The experiment was terminated on day 126 or earlier if ethical endpoints were met. Survival curves were analyzed using the Mantel Cox log-rank test.

[0243] Figure 1 shows the antitumor efficacy of the treatment on DU145 tumor xenografts. Tumor volumes were measured 2-3 times per week and are expressed as the mean tumor volume (± SEM). Each group initially consisted of 10 mice and was graphed until 6 or more animals remained in the group. As shown in Figure 1, at the dose administered, SPL9048 induced complete tumor regression and no regrowth was observed in any of the animals at day 126 when the experiment was terminated.

[0244] Figure 2 shows the effect of saline, cabazitaxel, SPL-9005 and SPL-9048 on DU145 tumor-bearing mouse body weight for male mice. Drugs were administered iv on days 1, 8 and 15 (indicated by vertical lines). Data represent the mean % body weight change from baseline (day 1) for each group; bars SEM. Graphs are shown for each group until there are fewer than 6 animals remaining in each group.

[0245] As shown in Figure 2, SPL9048 was generally well tolerated in mice (maximum weight loss -10% at day 20; neutral weight loss / gain after day 40). SPL9048 was also better tolerated than SPL9005 in male mice. For SPL9005, 8 / 10 male mice had weight loss >20% after the third dose at approximately day 25, while 2 / 10 male mice recovered to +5 / 10% starting weight after 40 days. However, in a separate study in female SCID mice, when administered at 25 mg / kg cabazitaxel equivalent, SPL9005 was better tolerated in female mice with a mean weight loss of less than 10%, suggesting a possible gender-related difference for this compound. MDA-MB-231 mouse xenograft breast cancer tumor model study

[0246] An MDA-MB-231 (human breast cancer cell line) mouse xenograft breast cancer model study was conducted to evaluate the antitumor efficacy profile of SPL9048 versus free cabazitaxel.

[0247] SPL-9048 was pre-weighed into glass vials, stored at 20°C until use, and dissolved in saline immediately prior to dosing. Cabazitaxel was prepared fresh for each day of dosing. An aliquot of the cabazitaxel concentrate was removed under sterile conditions and mixed with 13% ethanol diluent to create a 10 mg / ml working stock solution. A 1.8 mg / mL dosing solution was prepared from this working stock immediately prior to injection.

[0248] Female Balb / c nude mice (7 weeks old) were inoculated with 3.5 × 10 6 MDA-MB-231 cells were inoculated subcutaneously into the flank. Mice were weighed and tumors were measured twice weekly using electronic calipers. Tumor volumes (mm 3 ) is length(mm) / 2 x width(mm) 2 On day 10 after implantation (referred to as day 1), tumors of similar size (mean tumor volume 90 mm) were 3Mice bearing 10-mg / kg BALF were randomized into four groups of 10 animals. Treatment groups were saline, cabazitaxel (9 mg / kg), SPL-9048 (9 mg / kg) and SPL-9048 (10 mg / kg). All compounds were administered intravenously by tail vein injection at 0.1 ml / 10 g body weight on days 1, 8 and 15, except for cabazitaxel, which was administered at 0.05 ml / 10 g body weight. Mice were given a small dish containing nutritional supplements (mixed with food dust) daily. The experiment was terminated on day 113, or earlier if ethical endpoints were met.

[0249] Figure 3 shows the antitumor efficacy of treatment on MDA-MB-231 tumor xenografts. Tumor volumes were measured twice weekly and expressed as mean tumor volume (± SEM). Each group initially consisted of 10 mice, and graphs are shown until 7 or more animals remained in the group. As shown in Figure 3, SPL9048 induced complete tumor regression. Tumor regrowth in the cabazitaxel group was evident by day 43, with 9 of 10 tumors reaching the ethical tumor volume endpoint by day 98. Both doses of SPL-9048 significantly extended survival beyond that of cabazitaxel.

[0250] FIG. 4 shows the effect of saline, cabazitaxel and SPL-9048 on body weight in MDA-MB-231 tumor-bearing mice. Each group initially consisted of 10 mice. Drugs were administered iv on days 1, 8 and 15 (indicated by vertical lines). Data represent the mean % body weight change from baseline (day 1) for each group; bars SEM. Graphs are shown for each group until there were fewer than 7 animals remaining in each group. As shown in FIG. 4, SPL9048 was overall well tolerated and mean body weight loss did not exceed 6% in any group. Example 5: Toxicokinetic / pharmacokinetic studies

[0251] Single-dose toxicokinetic studies of SPL-9048 and SPL-9005 were conducted by intravenous bolus injection in rats with an observation period of 21 days. A control, 0.9% sodium chloride, was prepared and dispensed on the day of dosing. SPL-9048 and SPL-9005 were prepared at the appropriate concentrations to meet dose level requirements. Dosage formulations were prepared and dispensed on each dosing day and used within 3 hours of preparation. The required amount of test article was weighed and dissolved in an appropriate volume of saline by gentle swirling and the pH was recorded. Cabazitaxel (Jevtana®) was prepared at the appropriate concentration to meet dose level requirements. The desired amount (1.5 ml) of cabazitaxel concentrate (40 mg / ml) was aliquoted under sterile conditions and dissolved in an appropriate volume (4.5 mL) of 13% ethanol diluent at 15°C to 30°C to prepare a 10 mg / mL stock solution. This stock solution was further diluted with saline to produce the final dosing concentration within 30 minutes.

[0252] The animals used were male and female Sprague Dawley Crl:CD(SD) rats. The animals were 10-14 weeks old and weighed 327-565 g for males and 212-316 g for females at the start of dosing. The animals were acclimated to their designated enclosures for at least 4 days prior to the first day of dosing. The animals were assigned to groups by a stratified randomization scheme designed to achieve similar group mean body weights. Males and females were randomized separately. Animals in poor health or at the extremes of the weight range were not assigned to groups. PMI Nutrition International certified rodent chow no. 5CR4 was provided ad libitum throughout the study, except during designated procedures. The same diet in meal form was also provided when necessary. Municipal tap water, after treatment by reverse osmosis and ultraviolet irradiation, was made available ad libitum to each animal via an automated watering system, except during designated procedures. Water bottles were also provided when necessary. Animals were socially housed for psychological / environmental enrichment and provided items such as chews except when interrupted by study procedures / activities. Veterinary care was available throughout the course of the study.

[0253] Test and control articles were administered to appropriate animals via a single intravenous (slow bolus) injection into the tail vein in the amounts shown in the table below. References to the amount administered (mg / kg) for dendrimer compounds SPL-9048 and SPL-9005 are references to the amount of cabazitaxel that can theoretically be released by the dendrimer.

[0254] Animals were observed for 21 days after dose administration. Dose for each animal was based on the most recent body weight measurement. Animals were briefly restrained for dose administration but not sedated. Doses were administered using a syringe equipped with a needle. The first day of dosing for each group was designated as day 1. Comparator dosing formulations (Jevtana®, cabazitaxel) and test articles were maintained at 15-30°C during dosing. JPEG0007588065000058.jpg56147

[0255] Toxicokinetic parameters were estimated using Phoenix pharmacokinetic software. A non-compartmental approach consistent with the intravenous route of administration was used for parameter estimation. All parameters were generated from the combined SPL9048, SPL9005 and Jevtana® (cabazitaxel) concentrations in plasma whenever practical.

[0256] The following table and FIG. 5 provide details regarding the pharmacokinetic parameters for free cabazitaxel following administration of SPL9048 (a cabazitaxel-containing dendrimer of the present disclosure), or the comparator compounds, namely SPL9005 (a different cabazitaxel-containing dendrimer) and Jevtana®. JPEG0007588065000059.jpg86167

[0257] The free cabazitaxel plasma profiles for SPL9005 and SPL9048 were clearly different from those of Jevtana®. The results show that SPL9048 administered at 2.5 mg / kg resulted in a Cmax value of 36.89 ng / mL, a Tmax value of 6 hours, and an area under the curve (AUC) of 1239.99 ng.hr / mL. SPL9005 administered at 2.5 mg / kg resulted in a Cmax value of 9.29 ng / mL, a Tmax value of 2 hours, and an AUC of 548.96 ng.hr / mL. Jevtana® administered at 2.5 mg / kg resulted in a Cmax value of 801.05 ng.hr / mL, a Tmax value of 2 minutes, and an AUC of 679.99 ng.hr / mL. In the Jevtana® group, cabazitaxel was not measurable even more than 24 hours after administration of Jevtana®.

[0258] Thus, administration of SPL9048 reduces the risk of side effects or toxicity compared to Jevtana® due to its significantly lower Cmax. As shown by the AUC values ​​in the table above, administration of SPL9048 also increased overall exposure to cabazitaxel compared to Jevtana®. Both SPL-9048 and SPL-9005 have lower cabazitaxel Cmax than administration of an equivalent amount of Jevtana®. However, as demonstrated by the AUC levels, the amount of free cabazitaxel delivered by SPL9048 over the time course of the study was greater than that delivered by an equivalent dose of SPL9005 (i.e., containing an equivalent amount of cabazitaxel) (see table and Figure 4). SPL9048 demonstrated a superior pharmacokinetic profile consistent with reduced likelihood of side effects and increased efficacy at equivalent doses. Example 6: Toxicology Studies

[0259] A toxicology study was conducted in rats comparing the effects of SPL9048 and free cabazitaxel (Jevtana®).

[0260] SPL9048 and Jevtana® were administered at 1 mg / kg to rats, n=6 (3 males, 3 females). References to the administered amount (mg / kg) for the dendrimer compounds are references to the amount of cabazitaxel that can theoretically be released by the dendrimer.

[0261] As shown in FIG. 6, the results indicate that there is a separation of neutropenia at this dose level (1 mg / kg) in both male and female rats, as evidenced by the decline in values ​​seen with administration of Jevtana® (i.e., cabazitaxel) and the lesser / no decline in values ​​observed following administration of SPL9048 (see especially day 7). As expected, the rebound after day 7 appears to be dependent on the severity of neutropenia. In the 1 mg / kg Jevtana® (i.e., free cabazitaxel) group, there is a substantial rebound on day 14, but virtually no rebound in the 1 mg / kg SPL9048 group (or control), consistent with limited neutropenia in these groups. This indicates that SPL9048 is less likely to induce neutropenia and therefore less toxic in the clinic compared to administration of an equivalent dose of free cabazitaxel.

[0262] Similar results were seen in studies where SPL9048 and Jevtana® were delivered at 2.5 mg / kg of active agent. SPL9048 was found to cause less neutropenia at day 5 than Jevtana®. Reduced toxicity was observed with SPL9048 compared to Jevtana® / cabazitaxel. Test article-related hematology changes (reductions in leukocytes, neutrophils, lymphocytes, monocytes, eosinophils, platelets, and reticulocytes) were noted with 2.5 mg / kg SPL9048 and 2.5 mg / kg Jevtana® by day 2 in males and females and remained low through day 7. Reductions in these parameters were generally greater in rats receiving 2.5 mg / kg Jevtana®.

[0263] Treatment-related microscopic changes were observed in the thymus, bone marrow, and spleen of animals administered 2.5 mg / kg SPL9048 and 2.5 mg / kg Jevtana®; the severity of bone marrow and thymus findings was generally greater in Jevtana®-treated rats. Example 7: Comparative linker release rates in PBS at 37° C. and pH 7.4

[0264] A study was conducted to determine the release rate of cabazitaxel from certain dendrimer compounds in PBS (phosphate buffered saline) at 37° C. and pH 7.4. The compounds tested were: i) The compounds of the present disclosure, SPL9048 and SPL9049 (BHALys[Lys] 32 [α-DGA-cabazitaxel] 32† [ε-PEG 約1100 ] 32‡ SPL9049 differs from SPL9048 in that it contains a low molecular weight PEG group; and ii) Control cabazitaxel-containing dendrimer compounds, SPL9005 and SPL9006 (SPL9006 differs from SPL9048 in that it contains a MIDA (methyliminodiacetyl) linking group instead of the diglycolyl linking group (i.e., -N(Me)- instead of -O- present in the diglycolyl linker). SPL9006 was prepared by a synthetic method similar to that used to prepare SPL9048).

[0265] Results showing the % cabazitaxel released at 24 hours from two replicate experiments are shown in the table below along with the mean time to 50% release (or estimated mean time to 50% release based on the data points). % Cabazitaxel released in PBS at 37°C and pH 7.4: JPEG0007588065000060.jpg32126

[0266] Data for SPL9048 and SPL9049 at additional time points in Experiment 2 are also provided below: % Cabazitaxel released in PBS at 37°C and pH 7.4: JPEG0007588065000061.jpg56118

[0267] The results demonstrate the relative release rates of cabazitaxel from the dendrimers after administration: Comparative control SPL9005 releases about 12-15% of cabazitaxel over 24 hours in PBS at 37° C. and pH 7.4, comparative control SPL9006 (MIDA linker) releases about 8% of cabazitaxel over the same period in PBS at 37° C. and pH 7.4, disclosed compound SPL9048 releases about 40% of cabazitaxel over 24 hours in PBS at 37° C. and pH 7.4, and SPL9049 releases about 30-50% of cabazitaxel under the same conditions.

[0268] SPL9048 has also been observed to have increased stability in solution (e.g., with respect to precipitation) compared to SPL9049, which is due to the 1100 PEG, not PEGyl 2200 In addition to the excellent efficacy, toxicokinetic and pharmacokinetic properties observed with SPL9048, this property is an additional advantage of this drug-dendrimer conjugate. Example 8: Stability of Citric Acid Drug-Dendrimer Conjugate Compositions

[0269] A study conducted on drug release in dendrimer molecules loaded with different drugs in 0.1M citric acid at pH 3.5-6.5 confirmed maximum stability at room temperature and 4 degrees Celsius over 7 days at pH 4.5. The optimal range was 3.5-5.5 with less than 0.3% and 0.1% release at RT and 4C respectively. Another study was conducted to evaluate 10 different drug release inhibitors in dendrimer molecules loaded with different drugs in dog, mouse and human plasma. Citric acid was identified as the most effective inhibitor of drug release. Example 9: Comparison of SPL9048 with Abraxane® and Gemcitabine

[0270] A CAPAN-1 (human pancreatic adenocarcinoma cell line) mouse xenograft pancreatic cancer model study was conducted to evaluate the antitumor efficacy profile of SPL9048 compared to Abraxane® (albumin-bound paclitaxel) alone or in combination with gemcitabine.

[0271] SPL9048 and Cabazitaxel were prepared as described above. Gemcitabine and Abraxane® were obtained from the Peter MacCallum Cancer Centre pharmacy and dissolved in saline immediately prior to administration.

[0272] Female NOD-SCID interleukin-2 receptor gamma chain null mice (9 weeks old) were inoculated with 5 × 10 6 CAPAN-1 cells were inoculated subcutaneously into the flank. Mice were weighed and tumors were measured twice weekly using electronic calipers. Tumor volumes (mm 3 ) is length (mm) / 2 × width (mm) 2 On day 26 after implantation, tumors of similar size (mean tumor volume 100 mm) were 3 ) were randomized into eight groups of nine animals.

[0273] Abraxane® and SPL9048 were administered via tail vein iv injection and gemcitabine was administered by ip injection at 0.1 ml / 10 g body weight on days 1, 8 and 15. The experiment was terminated on day 107 or earlier if ethical endpoints were met. One mouse died immediately after Abraxane® injection on day 1 due to an injection error. All other treatments were well tolerated with no weight loss. Tumor growth data were analyzed by GraphPad Prism for ANOVA followed by Dunnett's post-hoc test. Groups were dosed as follows: 1. Saline - vehicle 2. Gemcitabine (80 mg / kg, ip) - vehicle (saline) 3. Abraxane® (40 mg / kg, iv) - Vehicle 4. Abraxane® (40 mg / kg, iv) + gemcitabine (80 mg / kg, ip) 7. SPL9048 (7.5 mg / kg, iv) - Vehicle 8. SPL9048 (7.5 mg / kg, iv) + gemcitabine (80 mg / kg, ip)

[0274] Figure 7 shows the antitumor efficacy of treatment on CAPAN-1 tumor xenografts. Tumor volumes were measured twice weekly and are expressed as mean tumor volume (±SEM). As shown in Figure 7, administration of SPL9048 alone or in combination with gemcitabine induced complete regression of CAPAN-1 tumors during the study period. Neither gemcitabine nor Abraxane® was effective in this model. SPL9048 treatment suppressed CAPAN-1 tumor growth more effectively than Abraxane® (P=0.004, Abraxane® vs. SPL-8732; P<0.0001 Mantel Cox regression analysis of Kaplan-Meier survival curves).

[0275] Abraxane® administered alone and in combination with gemcitabine inhibited CAPAN-1 tumor growth to a similar extent (% tumor growth inhibition at day 37 = 85% and 81%, respectively; Table 2). SPL9048 significantly extended survival compared to gemcitabine or Abraxane®. JPEG0007588065000062.jpg33123

[0276] Analysis was performed on day 37, the final day when all vehicle-treated animals remained in the study. Example 10: Phase 1 Clinical Trial - PK and Biomarkers

[0277] A Phase 1 dose escalation study was conducted to determine the appropriate dosing of SPL9048. Biomarker, PK and other data were collected from patients enrolled in the study. Patients were dosed every 3 weeks over 1 hour using an infusion pump. All patients had progressive metastatic disease. The patient population was heavily pretreated with a variety of chemotherapy agents as described in the table below. JPEG0007588065000063.jpg93155

[0278] Data in Figures 8 and 9 show that biomarker responses were 2 Figure 8 shows that this occurs at doses of SPL9048 as low as 10 mg / m 2 After multiple doses at 20 mg / m 2 Figure 9 shows the prostate cancer marker PSA continuing at cabazitaxel equivalent doses of 15 mg / m 2 The study also showed that CA-125, a marker for ovarian cancer, declined after two doses of 10 mg / kg / day, an important sign of efficacy.

[0279] The table below identifies patients on the trial, many of whom showed signs of stable disease. JPEG0007588065000064.jpg111130

[0280] Pharmacokinetic data for free cabazitaxel from the study are shown in the table below. In summary, after administration of SPL9048, free cabazitaxel Cmax was 1.0-1.2 times higher than the equivalent cabazitaxel dose of 20 mg / m 2 Approximately 3-10 times lower than Jevtana®. Cmax at 20 mg / ml cabazitaxel equivalent in three patients was measured to be 53.6, 15.8 and 17.6 ng / ml. JPEG0007588065000065.jpg33123

[0281] Pharmacokinetic data for total cabazitaxel (i.e., free cabazitaxel and dendrimer-bound cabazitaxel) from the study are shown in the table below. In summary, total cabazitaxel AUCinf after administration of SPL9048 is approximately 2000-4000 times greater than the equivalent cabazitaxel dose of Jevtana®. JPEG0007588065000066.jpg29142

[0282] Jevtana® numbers were calculated using the model described in Ferron G., et al Cancer Chemo Pharma (2013) 71:681-692.

Claims

1. i) a core unit (C); ii) a building unit (BU), wherein each building unit (BU) is a lysine residue or an analogue thereof; Including, said core unit is covalently bonded to two building units via amide bonds, each amide bond being formed between a nitrogen atom present in said core unit and a carbon atom of an acyl group present in a building unit; It is a generation 5 building unit dendrimer; The building units of different generations are covalently bonded to each other via amide bonds formed between a nitrogen atom present in one building unit and a carbon atom of an acyl group present in another building unit; iii) a plurality of first terminal groups (T1), each of which comprises a cabazitaxel residue covalently attached to a diglycolyl linker group; iv) a plurality of second end groups (T2), each comprising a PEG group having an average molecular weight in the range of 1000 to 2500 Daltons; A dendrimer further comprising at least one-third of the nitrogen atoms present in the outer building units are each covalently bonded to a first terminal group; At least one-third of the nitrogen atoms present in the outer building units are each covalently bonded to a second terminal group. A dendrimer, or a pharma- ceutically acceptable salt thereof.

2. 2. The dendrimer of claim 1 , wherein the core unit is: .

3. 3. A dendrimer according to claim 1 or 2, wherein said building units are each: ; where the acyl group of each building unit provides a covalent attachment point for bonding to the core or a previous generation building unit; and each nitrogen atom provides a covalent attachment point for covalently bonding to a subsequent generation building unit, the first terminal group or the second terminal group.

4. 4. The dendrimer of claim 3, wherein each of said building units is: .

5. 5. A dendrimer according to any one of claims 1 to 4 having five complete generations of building units.

6. 6. The dendrimer according to claim 1 , wherein each first end group (T1) is: .

7. 7. The dendrimer according to claim 1, wherein the second terminal groups each comprise a PEG group covalently bonded to a PEG linking group via an ether bond formed between a carbon atom present in the PEG group and an oxygen atom present in the PEG linking group (L1), and each second terminal group is covalently bonded to a building unit via an amide bond formed between a nitrogen atom present in a building unit and a carbon atom of an acyl group present in the PEG linking group.

8. 8. The dendrimer of claim 7, wherein each of said second end groups is: where the PEG group is a methoxy-terminated PEG having an average molecular weight in the range of 1750-2500 daltons.

9. 9. The dendrimer of claim 8, comprising a surface unit comprising outer building units attached to a first end group and a second end group, said surface unit having the following structure: , where the PEG group is a methoxy-terminated PEG having an average molecular weight in the range of 1750-2500 daltons.

10. 10. The dendrimer of claim 9 having from 28 to 32 surface units.

11. 11. The dendrimer according to claim 1, wherein at least 40% of the nitrogen atoms present in the outer building units are each covalently bonded to a first terminal group; and at least 40% of the nitrogen atoms present in the outer building units are each covalently bonded to a second terminal group.

12. 12. The dendrimer according to any one of claims 1 to 11, wherein 5 generations of building units are complete generations, the outer generations of building units providing 64 nitrogen atoms for covalent attachment to a first end group or a second end, 26 to 32 first end groups being covalently attached to one of said nitrogen atoms and 28 to 32 second end groups being covalently attached to each of said nitrogen atoms.

13. 13. A dendrimer according to any one of claims 1 to 12, wherein the cabazitaxel residues constitute a w / w % of the dendrimer in the range of 23% w / w to 28% w / w.

14. 14. A dendrimer according to any one of claims 1 to 13, which is: (Wherein, T1' represents a first terminal group as follows: or T1' represents H, and less than 5 of T1' are H; T2' represents the second end group: where the PEG group is a methoxy-terminated PEG having an average molecular weight in the range of 1750-2500 Daltons; or T2' represents H, and less than five of T2' are H.

15. 15. The dendrimer according to any one of claims 1 to 14, wherein the in vitro half-life of cabazitaxel release from the dendrimer in PBS at pH 7.4 and 37°C is in the range of 20 to 100 hours.

16. 16. The dendrimer of claim 15, wherein the in vitro half-life of cabazitaxel release from the dendrimer in PBS at pH 7.4 and 37° C. is in the range of 30 to 60 hours.

17. A composition comprising a plurality of dendrimers or pharma- ceutically acceptable salts thereof, The dendrimer is as defined in any one of claims 1 to 16, the average number of first end groups per dendrimer in the composition is in the range of 24 to 32; A composition, wherein the average number of second end groups per dendrimer in the composition is in the range of 24 to 32.

18. 18. The composition of claim 17, wherein the cabazitaxel residues constitute a w / w % of the dendrimer in the composition in the range of 23% w / w to 28% w / w.

19. 20. The composition of claim 18, which is a pharmaceutical composition and comprises a pharma- ceutically acceptable excipient.

20. i) a dendrimer according to any one of claims 1 to 16, or a pharma- ceutically acceptable salt thereof; and ii) a pharma- ceutically acceptable excipient.

23. A pharmaceutical composition comprising:

21. 21. The pharmaceutical composition of claim 20, which is a solid composition comprising a dendrimer according to any one of claims 1 to 16, a sugar and an acid, for reconstitution with a diluent.

22. 22. The pharmaceutical composition of claim 21, wherein the sugar is trehalose and the acid is citric acid.

23. 23. The composition of claim 21 or 22, wherein after reconstitution with a diluent, the reconstituted composition has a pH in the range of 3.5 to 5.

5.

24. 24. A pharmaceutical composition according to any one of claims 20 to 23, which is free or substantially free of polyethoxylated castor oil and polyethoxylated sorbitan monooleate.

25. 25. The pharmaceutical composition of any one of claims 20 to 24, formulated for administration as an infusion over a period of up to 30 minutes or formulated for administration as a bolus over a period of up to 5 minutes.

26. 26. A dendrimer according to any one of claims 1 to 16, or a pharmaceutical composition according to any one of claims 20 to 25, for use in the treatment of cancer.

27. 27. Use of a dendrimer according to any one of claims 1 to 16, or a composition according to any one of claims 20 to 25, in the manufacture of a medicament for treating cancer.

28. 28. The use of claim 27, wherein the cancer is selected from the group consisting of pancreatic cancer, prostate cancer, breast cancer and ovarian cancer.

29. 29. The use of claim 28, wherein the cancer is metastatic castration-resistant prostate cancer (mCRPC).

30. The therapeutically effective amount of the dendrimer is 10 to 100 mg / m 2 30. The use according to any one of claims 27 to 29, which is a range of body surface area.

31. The therapeutically effective amount of the dendrimer is 20 to 50 mg / m 2 31. The use of claim 30, which is a range of body surface areas.

32. The therapeutically effective amount of the dendrimer is 50 to 100 mg / m 2 32. The use of claim 31, which is a range of body surface areas.

33. 33. The use according to any one of claims 27 to 32, wherein the composition is administered as an infusion over a period of up to 30 minutes.

34. 34. The use according to any one of claims 27 to 33, wherein the dendrimer is administered in combination with a further therapeutic agent.

35. 35. The use of claim 34, wherein the additional therapeutic agent is an additional anti-cancer agent.

36. 36. The use according to any one of claims 27 to 35, wherein the dendrimer is (Wherein, T1' represents a first terminal group as follows: or T1' represents H, and less than 5 of T1' are H; T2' represents the second end group: where the PEG group is a methoxy-terminated PEG having an average molecular weight in the range of 1750-2500 Daltons; or T2' represents H, and less than five of T2' are H.

37. 37. The use of any one of claims 27 to 36, wherein administration of the dendrimer provides a therapeutically effective plasma concentration of cabazitaxel for a longer period of time compared to administration of an equivalent dose of free cabazitaxel.

38. 38. The use of any one of claims 27 to 37, wherein administration of the dendrimer provides a maximum concentration (Cmax) of cabazitaxel that is 20% or less than the maximum concentration provided by administration of an equivalent dose of free cabazitaxel.

39. 39. The use of any one of claims 27 to 38, wherein administration of the dendrimer provides a greater AUC of total cabazitaxel compared to direct administration of an equivalent dose of free cabazitaxel.

40. 40. The use of any one of claims 27 to 39, wherein administration of the dendrimer provides enhanced clinical efficacy compared to administration of an equivalent dose of free cabazitaxel.

41. The course of the dendrimer is administered at 20 or 25 mg / m 2 41. The use according to any one of claims 27 to 40, which provides enhanced clinical efficacy compared to three times weekly administration of cabazitaxel.

42. 42. The use according to any one of claims 27 to 41, wherein administration of the dendrimer results in a reduction in neutropenia, lymphopenia, anemia and / or thrombocytopenia compared to administration of an equivalent dose of free cabazitaxel.

43. The administration of the dendrimer is 20 or 25 mg / m 2 43. The use according to any one of claims 27 to 42, which results in a reduction in neutropenia, lymphopenia, anemia and / or thrombocytopenia compared to administration of cabazitaxel three times a week.

44. A method for producing a dendrimer according to any one of claims 1 to 16, comprising the steps of: a) the following cabazitaxel intermediates: , wherein X is —OH or a leaving group, or X together with the attached C(O) group forms a carboxylate salt, i) a core unit (C); ii) a building unit (BU), wherein each building unit (BU) is a lysine residue or an analogue thereof; Including, said core unit is covalently bonded to two building units via amide bonds, each amide bond being formed between a nitrogen atom present in said core unit and a carbon atom of an acyl group present in a building unit; The dendrimer is a 5 generation building unit dendrimer; The building units of different generations are covalently bonded to each other via amide bonds formed between a nitrogen atom present in one building unit and a carbon atom of an acyl group present in another building unit; The dendrimer has a plurality of second end groups (T2) each comprising a PEG group having an average molecular weight in the range of 1000-2500 Daltons.

1. A dendrimer intermediate further comprising: at least one-third of the nitrogen atoms present in the outer building units are each covalently bonded to a second end group; At least one-third of the nitrogen atoms present in the outer building units are unsubstituted and available for reaction with said cabazitaxel intermediate. a dendrimer intermediate, or a salt thereof; reacting under amide coupling conditions; or b) a PEG intermediate which is wherein the PEG group is a PEG-containing group having an average molecular weight in the range of 1000 to 2500 Daltons; X is -OH or a leaving group, or X together with the attached C(O) group forms a carboxylate salt; i) a core unit (C); ii) a building unit (BU), wherein each building unit (BU) is a lysine residue or an analogue thereof; Including, said core unit is covalently bonded to two building units via amide bonds, each amide bond being formed between a nitrogen atom present in said core unit and a carbon atom of an acyl group present in a building unit; The dendrimer is a 5 generation building unit dendrimer; The building units of different generations are covalently bonded to each other via amide bonds formed between a nitrogen atom present in one building unit and a carbon atom of an acyl group present in another building unit; The dendrimer comprises a plurality of first end groups (T1), each of which comprises a cabazitaxel residue covalently attached to a diglycolyl linker group.

1. A dendrimer intermediate further comprising: at least one-third of the nitrogen atoms present in the outer building units are each covalently bonded to a first terminal group; At least one-third of the nitrogen atoms present in the outer building units are unsubstituted; a dendrimer intermediate, or a salt thereof; reacting under amide coupling conditions; or c) a surface unit intermediate which is wherein the PEG group is a PEG-containing group having an average molecular weight in the range of 1000 to 2500 Daltons; X is -OH or a leaving group, or X together with the attached C(O) group forms a carboxylate salt; i) a core unit (C); ii) a building unit (BU), wherein each building unit (BU) is a lysine residue or an analogue thereof; Including, said core unit is covalently bonded to two building units via amide bonds, each amide bond being formed between a nitrogen atom present in said core unit and a carbon atom of an acyl group present in a building unit; A fourth generation building unit dendrimer intermediate; The building units of different generations are covalently bonded to each other via amide bonds formed between a nitrogen atom present in one building unit and a carbon atom of an acyl group present in another building unit; The nitrogen atoms present in the outer building units of the dendrimer intermediate are unsubstituted; a dendrimer intermediate, or a salt thereof; reacting under amide coupling conditions.

45. The following dendrimers where X is -OH or a leaving group, or X together with the C(O) group to which it is attached forms a carboxylate salt. An intermediate for the manufacture of.

46. The following dendrimers wherein the PEG group is a PEG-containing group having an average molecular weight in the range of 1000 to 2500 Daltons; X is -OH or a leaving group, or X together with the C(O) group to which it is attached forms a carboxylate salt. An intermediate for the manufacture of.

Citation Information

Patent Citations

  • polymer

    JP2014520105A

  • Improved hybrid telodendrimers

    WO2018053316A1